var title_f6_14_6368="Spread odontogenic infection";
var content_f6_14_6368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Routes of spread of odontogenic orofacial infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 188px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spread occurs along planes of least resistance. Top panel: Coronal section in the region of the first molar teeth: a, maxillary antrum; b, nasal cavity; c, palatal plate; d, sublingual space (above the mylohyoid muscle); e, submandibular space (below the mylohyoid muscle); f, intraoral presentation with infection spreading through the buccal plates inside the attachment of the buccinator muscle; g, extraoral presentation to buccal space with infection spreading through the buccal plates outside the attachment of the buccinator muscle. Bottom panel: Lingual aspect of the mandible: a, apices of the involved tooth above the myohyoid muscle, with spread of infection to the sublingual space; b, apices of involved tooth below the mylohyoid muscle, with spread of infection into the submandibular space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Chow, AW, Roser, SM, Brady, FA, Ann Intern Med 1978; 88:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6368=[""].join("\n");
var outline_f6_14_6368=null;
var title_f6_14_6369="Contacts diphtheria protocol";
var content_f6_14_6369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Respiratory diphtheria: Recommendations for case management and investigation of close contacts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 488px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Strict isolation should be maintained until two cultures are negative at least 24 hours apart after completion of antimicrobial therapy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Equine diphtheria antitoxin can be obtained from either the Centers for Disease Control and Prevention (1-404-639-2889), or Connaught Laboratories, Swiftwater, PA. Before administration, patients should be tested for sensitivity to horse serum and, if necessary, desensitized. The recommended dosage and route of administration depend on the extent and duration of disease.",
"      <br>",
"       &Delta; See text for dosing.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Close contacts include household members and other persons with a history of direct contact with a case-patient (eg, caretakers, relatives, or friends who regularly visit the home) as well as medical staff exposed to oral or respiratory secretions of a case-patient.",
"        <br>",
"         &sect; See text for dosing.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6369=[""].join("\n");
var outline_f6_14_6369=null;
var title_f6_14_6370="Treatment protocols for non-small cell lung cancer";
var content_f6_14_6370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6370/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/14/6370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6926423\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with non-small cell lung cancer.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with non-small cell lung cancer. Additional regimens may be added over time, particularly as treatment for non-small cell lung cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with non-small cell lung cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119318348\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242762\">",
"    <span class=\"h2\">",
"     Carboplatin plus docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69824 \" href=\"UTD.htm?3/35/3646\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242787\">",
"    <span class=\"h2\">",
"     Carboplatin plus pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81778 \" href=\"UTD.htm?12/40/12942\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242812\">",
"    <span class=\"h2\">",
"     Cetuximab, vinorelbine, and cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65122 \" href=\"UTD.htm?21/56/22414\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242837\">",
"    <span class=\"h2\">",
"     Cisplatin plus pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67209 \" href=\"UTD.htm?12/35/12862\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242862\">",
"    <span class=\"h2\">",
"     Gemcitabine plus carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54959 \" href=\"UTD.htm?12/5/12382\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242887\">",
"    <span class=\"h2\">",
"     Gemcitabine plus cisplatin (GC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef64774 \" href=\"UTD.htm?8/54/9070\">",
"     table 6",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242937\">",
"    <span class=\"h2\">",
"     Paclitaxel carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56125 \" href=\"UTD.htm?9/49/10014\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242912\">",
"    <span class=\"h2\">",
"     Paclitaxel, carboplatin, and bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76013 \" href=\"UTD.htm?24/25/24990\">",
"     table 8",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936242962\">",
"    <span class=\"h2\">",
"     Vinorelbine plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef59705 \" href=\"UTD.htm?9/26/9646\">",
"     table 9",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85689 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6370=[""].join("\n");
var outline_f6_14_6370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6926423\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H119318348\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242762\">",
"      Carboplatin plus docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242787\">",
"      Carboplatin plus pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242812\">",
"      Cetuximab, vinorelbine, and cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242837\">",
"      Cisplatin plus pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242862\">",
"      Gemcitabine plus carboplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242887\">",
"      Gemcitabine plus cisplatin (GC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242937\">",
"      Paclitaxel carboplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242912\">",
"      Paclitaxel, carboplatin, and bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H936242962\">",
"      Vinorelbine plus cisplatin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85689|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/35/3646\" title=\"table 1\">",
"      Carboplatin plus docetaxel for adv non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/40/12942\" title=\"table 2\">",
"      Carboplatin plus pemetrexed for non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/56/22414\" title=\"table 3\">",
"      Cetuximab vinorelbine and cisplatin chemotherapy for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/35/12862\" title=\"table 4\">",
"      Cisplatin plus pemetrexed NSCLC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/5/12382\" title=\"table 5\">",
"      Gemcitabine plus carboplatin for non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/54/9070\" title=\"table 6\">",
"      Gemcitabine plus cisplatin regimen for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/49/10014\" title=\"table 7\">",
"      Paclitaxel and carboplatin for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24990\" title=\"table 8\">",
"      Paclitaxel-carboplatin- bevacizumab chemotherapy for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9646\" title=\"table 9\">",
"      Adjuvant vinorelbine plus cisplatin regimen for NSCLC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6371="Gas and bloating";
var content_f6_14_6371=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Gas and bloating (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/14/6371/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6371/contributors\" id=\"au6555\">",
"       Stephen E Goldfinger, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/14/6371/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6371/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/14/6371/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6371/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/14/6371?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GAS AND BLOATING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Some people feel that they pass too much gas or burp too frequently, both of which can be a source of embarrassment and discomfort. The average adult produces about one to three pints of gas each day, which is passed through the anus 14 to 23 times per day. Burping occasionally before or after meals is also normal.",
"    </p>",
"    <p>",
"     The amount of gas produced by the body depends upon your diet and other individual factors. However, most people who complain of excessive gas do not produce more gas than the average person. Instead, they are more aware of normal amounts of gas. On the other hand, certain foods and medical conditions can cause you to make excessive amounts of gas.",
"    </p>",
"    <p>",
"     This article reviews the sources of intestinal gas, conditions that increase sensitivity to gas, and measures to reduce gas production. A more detailed review of this topic is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24872?source=see_link\">",
"      \"Intestinal gas and bloating\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SOURCES OF GAS",
"     </span>",
"    </p>",
"    <p>",
"     There are two primary sources of intestinal gas: gas that is ingested (mostly swallowed air) and gas that is produced by bacteria in the colon.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Air swallowing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Air swallowing is the major source of gas in the stomach. It is normal to swallow a small amount of air when eating and drinking and when swallowing saliva. You may swallow larger amounts of air when eating food rapidly, gulping liquids, chewing gum, or smoking.",
"    </p>",
"    <p>",
"     Most swallowed air is eliminated by belching so that only a relatively small amount of air passes from the stomach into the small intestine (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"      figure 1",
"     </a>",
"     ). Your posture may influence how much air passes to the small intestine.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       When sitting up, most swallowed air passes back up the esophagus and out of the mouth, which can cause you to belch.",
"      </li>",
"      <li>",
"       When lying down, swallowed air tends to pass into the small intestine, which can cause you to pass gas.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Belching may be voluntary or occur unintentionally. Involuntary belching is a normal process that typically occurs after eating to release air that enlarges or stretches the stomach. Belching is more common with certain foods that relax the ring-shaped muscle (sphincter) around the lower end of the esophagus where it joins the stomach. Such foods include peppermint, chocolate, and fats.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Bacterial production",
"     </span>",
"     &nbsp;&mdash;&nbsp;The colon normally provides a home for billions of harmless bacteria, some of which support the health of the bowel. Certain carbohydrates are incompletely digested by enzymes in the stomach and intestines, allowing bacteria to digest them. For example, cabbage, Brussels sprouts, and broccoli contain raffinose, a carbohydrate that is poorly digested. These foods tend to cause more gas and flatulence because the raffinose is digested by bacteria once it reaches the colon. The by-products of this process include odorless gases, such as carbon dioxide, hydrogen, and methane. Minor components of gas have an unpleasant odor, including trace amounts of sulfur.",
"    </p>",
"    <p>",
"     Some people are not able to digest certain carbohydrates. A classic example is lactose, the major sugar contained in dairy products (",
"     <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"      table 1",
"     </a>",
"     ). Thus, consuming large amounts of lactose may lead to increased gas production, along with cramping and diarrhea (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Lactose intolerance'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Certain diseases can also cause excessive bloating and gas. For example, people with diabetes or scleroderma may, over time, have slowing in the activity of the small intestine. This can lead to bacterial overgrowth within the bowel, with poor digestion of carbohydrates and other nutrients. However, even in the absence of apparent disease, some people tend to harbor large numbers of bacteria in their small bowel and are prone to develop excessive gas.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      GAS AND BLOATING SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Some people feel they pass an excessive amount of gas or burp too frequently. Other people notice bloating and crampy abdominal pain. You may feel this pain in areas where gas can become trapped (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"      figure 1",
"     </a>",
"     ), such as in bends in the colon, which occur naturally in the area under the liver (upper to mid-right part of the abdomen), and in the area under the spleen (upper to mid left part of the abdomen).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      SENSITIVITY TO GAS",
"     </span>",
"    </p>",
"    <p>",
"     The link between gas, belching, and the actual amount of gas in the intestines is not always clear. The vast majority of people who are bothered by gas-related symptoms do",
"     <strong>",
"      not",
"     </strong>",
"     have an excessive amount of gas in the intestine, but rather they have an increased sensitivity to normal amounts of gas in the intestine. This can happen in a variety of circumstances.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Irritable bowel syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with irritable bowel syndrome (IBS) are sensitive to normal amounts of gas. Nerves that carry messages from the bowel may be overactive in people with IBS, so that normal amounts of gas or movement in the intestines feels painful or overactive. The primary symptoms of IBS are abdominal pain and changes in bowel habits (such as diarrhea",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     constipation). Many people also complain of bloating. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some people with severe IBS feel better when treated with medications that decrease the painful feelings coming from the intestine (such as low doses of imipramine or nortriptyline).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Functional dyspepsia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dyspepsia is the term for recurrent or persistent pain or discomfort in the upper abdomen. Approximately 25 percent of people in the United States and other western countries experience dyspepsia. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"      \"Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Dyspepsia can arise from various underlying conditions, the most common of which is \"functional\" (or \"nonulcer\") dyspepsia. Functional dyspepsia causes abdominal pain without an identifiable cause, probably due to an increased sensitivity to contents within the stomach.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Irritation of the anus or esophagus",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have irritation around their anus due to hemorrhoids or other problems may also experience more discomfort when they pass gas. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"      \"Patient information: Hemorrhoids (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Similarly, people who have irritation of the esophagus (esophagitis) may find burping painful. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CAUSES OF INCREASED GAS",
"     </span>",
"    </p>",
"    <p>",
"     The vast majority of people who are bothered by gas do not produce excessive amounts of gas. However, there are several conditions that may lead to increased gas formation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Swallowed air",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic, repeated belching can occur if you swallow large amounts of air (ie, aerophagia). Aerophagia is typically an unconscious process, and is often associated with emotional stress. Treatment focuses on decreasing air swallowing by reducing anxiety, when it is considered to be a cause, as well as on eating slowly without gulping and avoiding carbonated beverages, chewing gum, and smoking.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Foods that cause gas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several foods contain the carbohydrate raffinose, which is poorly digested and can increases gas production. Foods that contain raffinose include beans, cabbage, cauliflower, Brussels sprouts, broccoli, and asparagus. Avoiding these foods or eating them infrequently may reduce the amount of gas you produce.",
"    </p>",
"    <p>",
"     Starch and soluble fiber can also contribute increase gas. Potatoes, corn, noodles, and wheat produce gas while rice does not. Soluble fiber (found in oat bran, peas and other legumes, beans, and most fruit) also causes gas. Some laxatives contain soluble fiber and may cause gas, particularly during the first few weeks of use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Lactose intolerance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lactose intolerance occurs when your body has difficulty digesting lactose, the sugar found in most milk-based products (",
"     <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"      table 1",
"     </a>",
"     ). Symptoms of lactose intolerance include diarrhea, abdominal pain, and flatulence after consuming milk or milk-containing products. More detailed information about lactose intolerance is available separately.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Intolerance to food sugars",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people are intolerant of sugars contained in certain foods. Two common examples are fructose (contained in dried fruit, honey, sucrose, onions, artichokes, and many foods and drinks that contain \"high fructose corn syrup\") and sorbitol (a sugar substitute contained in some sugar free candies and chewing gum).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Diseases associated with increased gas",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of diseases can cause difficulty absorbing carbohydrates, which can lead to increased gas. This problem can occur in people with celiac disease (a disease caused by intolerance to a protein contained in wheat), short bowel syndrome, and in some rare disorders. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      GAS AND BLOATING DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with gas and bloating do not need to have any testing. However, symptoms such as diarrhea, weight loss, abdominal pain, anemia, blood in the stool, lack of appetite, fever, or vomiting can be warning signs of a more serious problem; people with one or more of these symptoms usually require testing.",
"    </p>",
"    <p>",
"     Tests may include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Examination of stool for blood, abnormally high levels of fat (steatorrhea), or a parasite (eg, Giardia). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=see_link\">",
"        \"Patient information: Giardia (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A lactose tolerance test, described above (see",
"       <a class=\"local\" href=\"#H13\">",
"        'Lactose intolerance'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       X-ray examination of the small intestine.",
"      </li>",
"      <li>",
"       A test to examine the inside of the stomach",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       colon (upper endoscopy, sigmoidoscopy, or colonoscopy). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"        \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"        \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"        \"Patient information: Colonoscopy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A blood test for celiac disease. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"        \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      GAS AND BLOATING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Several measures can help to reduce bothersome gas.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Diet recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Avoid foods that appear to aggravate your symptoms. These may include milk and dairy products, certain fruits or vegetables, whole grains, artificial sweeteners,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     carbonated beverages. Keep a record of foods and beverages to help to pinpoint which foods are bothersome (",
"     <a class=\"graphic graphic_figure graphicRef58605 \" href=\"UTD.htm?26/37/27231\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If you are lactose intolerant, do not consume products that contain lactose (",
"     <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"      table 1",
"     </a>",
"     ) or use a lactose-digestive aid, such as lactose-reduced milk or over-the-counter lactase supplements (eg, Lactaid&reg; tablets or liquid). Take a calcium supplement if you avoid milk products. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Over-the-counter medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Try an over-the-counter product that contains simethicone, such as certain antacids (eg, Maalox&reg; Anti-Gas, Mylanta&reg; Gas, Gas-X&reg;, Phazyme&reg;). Simethicone causes gas bubbles to break up and is widely used to relieve gas, although its benefit is questionable.",
"    </p>",
"    <p>",
"     Try an over-the-counter product that contains activated charcoal (eg, CharcoCaps&reg;, CharcoAid&reg;). The benefit of activated charcoal is unclear, although it is reasonable to try.",
"    </p>",
"    <p>",
"     Try Beano&trade;, an over-the-counter preparation that helps to breakdown certain complex carbohydrates. This treatment may be effective in reducing gas after eating beans or other vegetables that contain raffinose.",
"    </p>",
"    <p>",
"     Try bismuth subsalicylate (eg, Pepto-Bismol&reg;) to reduce the odor of unpleasant smelling gas.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Deodorizing products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Consider a device to deodorize gas, such as underwear made from carbon fiber (eg, Under-Ease protective underwear {Under-Tec, Corp} and GasMedic&reg; underair brief {Dairiair, LLC}). These appear to be effective but are expensive. Charcoal lined cushions or pads are also available, but may not be as effective.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287461216\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254998\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=see_link\">",
"      Patient information: Gas and bloating (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/26/11684?source=see_link\">",
"      Patient information: Lactose intolerance (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H255013\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=see_link\">",
"      Patient information: Giardia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24872?source=see_link\">",
"      Intestinal gas and bloating",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"      Lactose intolerance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/gas/index.htm\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/gas/index.htm",
"       </a>",
"       , also available in Spanish)",
"      </li>",
"      <li>",
"       The American Gastroenterological Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/gas-in-the-digestive-tract\">",
"        file://www.gastro.org/patient-center/digestive-conditions/gas-in-the-digestive-tract",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/14/6371/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/14/6371?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6371/abstract/1\">",
"      Choi YK, Johlin FC Jr, Summers RW, et al. Fructose intolerance: an under-recognized problem. Am J Gastroenterol 2003; 98:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6371/abstract/2\">",
"      Suarez FL, Furne JK, Springfield J, Levitt MD. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology 1998; 114:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6371/abstract/3\">",
"      Ohge H, Furne JK, Springfield J, et al. Effectiveness of devices purported to reduce flatus odor. Am J Gastroenterol 2005; 100:397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_14_6371=[""].join("\n");
var outline_f6_14_6371=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GAS AND BLOATING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SOURCES OF GAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           GAS AND BLOATING SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           SENSITIVITY TO GAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CAUSES OF INCREASED GAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           GAS AND BLOATING DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           GAS AND BLOATING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\" title=\"figure 1\">",
"           Abdomen anatomy adult PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/37/27231\" title=\"figure 2\">",
"           Diet diary PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?32/38/33388\" title=\"table 1\">",
"           Lactose content of different foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6372="Known drug metab enzymes";
var content_f6_14_6372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Drug-metabolizing enzymes exhibiting clinically relevant genetic polymorphisms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most drug-metabolizing enzymes exhibit clinically relevant genetic polymorphisms. Essentially all of the major human enzymes responsible for modification of functional groups [classified as phase I reactions (Panel A)] or conjugation with endogenous substituents [classified as phase II reactions (Panel B)] exhibit common polymorphisms at the genomic level; those enzyme polymorphisms that have already been associated with changes in drug effects are separated from the corresponding pie charts. The percentage of phase I and phase II metabolism of drugs that each enzyme contributes is estimated by the relative size of each section of the corresponding chart.",
"    <div class=\"footnotes\">",
"     ADH: alcohol dehydrogenase; ALDH: aldehyde dehydrogenase; CYP: cytochrome P450; DPD: dihydropyrimidine dehydrogenase; NQO1: NADPH:quinone oxidoreductase or DT diaphorase; COMT: catechol O-methyltransferase; GST: glutathione S-transferase; HMT: histamine methyltransferase; NAT: N-acetyltransferase; STs: sulfotransferases; TPMT: thiopurine methyltransferase; UGTs: uridine 5'-triphosphate glucuronosyltransferases.",
"    </div>",
"    <div class=\"reference\">",
"     From: Evans WE, Relling MV. Pharmacogenetics: Translating functional geneomics into rational therpaeutics. Science 1999; 286:487. Reprinted with permission from AAAS. Copyright &copy; 1999. Readers may view, browse, and/or download material for temporary copying purposes only, provided these uses are for noncommercial personal purposes. Except as provided by law, this material may not be further reproduced, distributed, transmitted, modified, adapted, performed, displayed, published, or sold in whole or in part, without prior written permission from the publisher.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6372=[""].join("\n");
var outline_f6_14_6372=null;
var title_f6_14_6373="Jones metroplasty E";
var content_f6_14_6373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty E",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (E) Using the lightest possible suture, the third layer approximates the superficial myometrium and serosa. The rough edges should be imbricated as much as possible to prevent adhesions along the suture line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6373=[""].join("\n");
var outline_f6_14_6373=null;
var title_f6_14_6374="Atracurium: Drug information";
var content_f6_14_6374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atracurium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/59/34739?source=see_link\">",
"    see \"Atracurium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/15/42229?source=see_link\">",
"    see \"Atracurium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atracurium Besylate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Nondepolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only (not to be used I.M.): Dose to effect; doses must be individualized due to interpatient variability; use ideal body weight for obese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adjunct to surgical anesthesia (neuromuscular blockade):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (bolus):",
"     </i>",
"     0.4-0.5 mg/kg, then 0.08-0.1 mg/kg 20-45 minutes after initial dose to maintain neuromuscular block; repeat dose at 15- to 25-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial dose after succinylcholine for intubation (balanced anesthesia): 0.2-0.4 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pretreatment/priming: I.V.: 10% of intubating dose given 3-5 minutes before initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. continuous infusion:",
"     </i>",
"     Initial: 9-10 mcg/kg/minute at initial signs of recovery from bolus dose; block is usually maintained by a rate of 5-9 mcg/kg/minute under balanced anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU neuromuscular blockade:",
"     </b>",
"     I.V.: Initial (bolus) 0.4-0.5 mg/kg, followed by I.V. continuous infusion at an initial rate of 5-10 mcg/kg/minute; block is usually maintained by rate of 11-13 mcg/kg/minute (rates for pediatric patients may be higher).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/15/42229?source=see_link\">",
"      see \"Atracurium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Adjunct to surgical anesthesia:",
"     </b>",
"     I.V. (not to be used I.M.): Dose to effect; doses must be individualized due to interpatient variability; use ideal body weight for obese patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 1 month to 2 years:",
"     </i>",
"     Initial: 0.3-0.4 mg/kg followed by maintenance doses as needed to maintain neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &gt;2 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as besylate: 10 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as besylate [preservative free]: 10 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be given undiluted as a bolus injection; not for I.M. injection due to tissue irritation; administration via infusion requires the use of an infusion pump; use infusion solutions within 24 hours of preparation",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F137889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR;",
"     <b>",
"      variable (consult detailed reference):",
"     </b>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amiodarone, cefazolin, cefuroxime, cimetidine, dobutamine, dopamine, epinephrine, esmolol, etomidate, fenoldopam, fentanyl, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, isoproterenol, lorazepam, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, ranitidine, sodium nitroprusside, sulfamethoxazole/trimethoprim, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, fentanyl, midazolam, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery; to facilitate mechanical ventilation in ICU patients; does not relieve pain or produce sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2973355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on",
"       <b>",
"        high alert",
"       </b>",
"       (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild, rare, and generally suggestive of histamine release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%: Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Bronchial secretions, erythema, hives, itching, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reaction, bradycardia, bronchospasm, dyspnea, hypotension, injection site reaction, seizure, acute quadriplegic myopathy syndrome (prolonged use), laryngospasm, myositis ossificans (prolonged use), tachycardia, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Causes of prolonged neuromuscular blockade:",
"     </b>",
"     Excessive drug administration; cumulative drug effect, metabolism/excretion decreased (hepatic and/or renal impairment); accumulation of active metabolites; electrolyte imbalance (hypokalemia, hypocalcemia, hypermagnesemia, hypernatremia); hypothermia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atracurium besylate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: May be more common with atracurium than with other neuromuscular-blocking agents since it has no clinically-significant effects on heart rate to counteract the bradycardia produced by anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Resistance may occur in burn patients (&gt;30% of body) for period of 5-70 days postinjury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may antagonize neuromuscular blockade: Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may potentiate neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immobilized patients:  Resistance may occur in patients who are immobilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Resistance may develop with chronic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Histamine release: Reduce initial dosage and inject slowly (over 1-2 minutes) in patients in whom substantial histamine release would be potentially hazardous (eg, patients with clinically-important cardiovascular disease).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Small amounts of atracurium have been shown to cross the placenta when given to women during cesarean section.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Atracurium Besylate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $9.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs (heart rate, blood pressure, respiratory rate); degree of muscle relaxation (via peripheral nerve stimulator and presence of spontaneous movement); renal function (serum creatinine, BUN) and liver function when in ICU",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In the ICU setting, prolonged paralysis and generalized myopathy, following discontinuation of agent, may be minimized by appropriately monitoring degree of blockade.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aculex (KP);",
"     </li>",
"     <li>",
"      Atra (TH);",
"     </li>",
"     <li>",
"      Atracor (PH);",
"     </li>",
"     <li>",
"      Atralex (MY);",
"     </li>",
"     <li>",
"      Farelax (ID);",
"     </li>",
"     <li>",
"      Genso (TW);",
"     </li>",
"     <li>",
"      Notrixum (ID);",
"     </li>",
"     <li>",
"      Relatrac (CO, MX, PE);",
"     </li>",
"     <li>",
"      Tracrium (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CN, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Tracur (BR);",
"     </li>",
"     <li>",
"      Tracurix (AR);",
"     </li>",
"     <li>",
"      Tramus (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (dose dependent): 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Recovery begins in 20-35 minutes following initial dose of 0.4-0.5 mg/kg under balanced anesthesia; recovery to 95% of control takes 60-70 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes ester hydrolysis and Hofmann elimination (nonbiologic process independent of renal, hepatic, or enzymatic function); metabolites have no neuromuscular blocking properties; laudanosine, a product of Hofmann elimination, is a CNS stimulant and can accumulate with prolonged use. Laudanosine is hepatically metabolized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Adults: Initial (distribution): 2 minutes; Terminal: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meretoja OA, Taivainen T, Jalkanen L, et al, &ldquo;Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(5):605-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/7826787/pubmed\" id=\"7826787\" target=\"_blank\">",
"        7826787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):142-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/11902255/pubmed\" id=\"11902255\" target=\"_blank\">",
"        11902255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peat SJ, Potter DR, and Hunter JM, &ldquo;The Prolonged Use of Atracurium in a Patient With Tetanus,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1988, 43(11):962-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/3213921/pubmed\" id=\"3213921\" target=\"_blank\">",
"        3213921",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yate PM, Flynn PJ, Arnold RW, et al, &ldquo;Clinical Experience and Plasma Laudanosine Concentrations During the Infusion of Atracurium in the Intensive Therapy Unit,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1987, 59(2):211-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/14/6374/abstract-text/3548792/pubmed\" id=\"3548792\" target=\"_blank\">",
"        3548792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8973 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6374=[""].join("\n");
var outline_f6_14_6374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137882\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137864\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137876\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137865\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137866\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137867\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137843\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137829\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137846\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137889\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137844\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973355\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137880\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137849\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137833\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298793\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137839\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137871\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323004\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137841\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869366\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137832\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137848\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8973|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/59/34739?source=related_link\">",
"      Atracurium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/15/42229?source=related_link\">",
"      Atracurium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6375="Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease";
var content_f6_14_6375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Lawrence M Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6375/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6375/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/14/6375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitation of crystals of calcium pyrophosphate dihydrate (CPPD) in connective tissues may be asymptomatic or may be associated with several clinical syndromes. These disorders comprise the spectrum of calcium pyrophosphate crystal deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/1\">",
"     1",
"    </a>",
"    ]. Alternative names representing specific clinical or radiographic features have retained some popularity but are of limited applicability. These include pseudogout, chondrocalcinosis, and pyrophosphate arthropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudogout accurately describes acute attacks of CPPD crystal-induced synovitis, which clinically resemble urate gout. However, the majority of individuals with CPPD crystal deposition never experience such episodes.",
"     </li>",
"     <li>",
"      Chondrocalcinosis refers to radiographic calcification in hyaline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrocartilage. It is commonly present in patients with CPPD crystal deposition disease but is neither absolutely specific for CPPD nor universal among affected patients.",
"     </li>",
"     <li>",
"      Pyrophosphate arthropathy is sometimes applied to the joint disease or radiographic abnormalities accompanying CPPD crystal deposition. This name, however, has little justification in terms of the pathologic anatomy of the disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and etiology of CPPD crystal deposition disease will be reviewed here. The clinical manifestations, diagnosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18134?source=see_link\">",
"     \"Treatment of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium pyrophosphate crystal deposition disease is a disease of older adults, with an average age of 72 years in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/1\">",
"     1",
"    </a>",
"    ]. Radiographic surveys also demonstrate an age-related increase in the prevalence of articular chondrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This was illustrated in a report that supplemented radiographs of the knees with x-rays of the hands, wrists, and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence of radiographic calcium pyrophosphate deposition according to age was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      65 to 74 years &mdash; 15 percent",
"     </li>",
"     <li>",
"      75 to 84 years &mdash; 36 percent",
"     </li>",
"     <li>",
"      &gt;84 years &mdash; almost 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Precise prevalence data concerning younger patients are not available.",
"   </p>",
"   <p>",
"    The gender distribution of CPPD crystal deposition disease has differed among large series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ], but no major sex predominance appears likely. Attacks of pseudogout occur more frequently in men, while pseudo-osteoarthritis is more common in women (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress has been made in understanding the pathogenesis of CPPD crystal formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/1\">",
"     1",
"    </a>",
"    ]. CPPD crystal formation is initiated in cartilage located near the surface of chondrocytes. Chondrocytes are cells that are embedded in and contribute to the collagen- and proteoglycan-containing cartilage matrix. Crystal formation may reflect elevated levels of either calcium or pyrophosphate (PPi), matrix changes that enhance local CaPPi supersaturation, or a combination of these factors.",
"   </p>",
"   <p>",
"    Although aberrations in both mineral and organic phase metabolism are probably variably involved in CPPD crystal deposition disease, two promising lines of inquiry are based upon data suggesting that the disorder is associated with excessive cartilage PPi production leading to local calcium pyrophosphate supersaturation and CPPD crystal formation or deposition.",
"   </p>",
"   <p>",
"    The first of these relates to the observation that augmented PPi production in cartilage extracts from some patients appears to result from overactivity of one or more of a group of nucleoside triphosphate pyrophosphohydrolase (NTPPPH) enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. These enzymes are associated with the external surface of the chondrocyte cell membrane and are capable of catalyzing the production of PPi by the extracellular hydrolysis of nucleoside triphosphates, especially ATP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/10\">",
"     10",
"    </a>",
"    ]. One function of extracellular PPi appears to be to bind to and to inhibit the growth of basic calcium phosphate (BCP) crystals. Study of a mouse strain model (&ldquo;tiptoe-walking&rdquo; mouse), in which point mutation and deficiency of the NTPPPH enzyme PC-1 (phosphodiesterase; nucleoside pyrophosphatase) is associated with excessive axial skeletal mineralization with BCP crystals and eventual myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/11\">",
"     11",
"    </a>",
"    ], provides evidence that deficiency in NTPPPH enzyme activity can disrupt the normal reciprocal relationship between extracellular PPi levels and BCP crystal growth and deposition. This, in turn, suggests that, in CPPD, excessive PPi levels arising from NTPPPH overactivity could provide the substrate for CPPD crystal formation in the immediate environment of chondrocytes.",
"   </p>",
"   <p>",
"    One possible mechanism leading to CPPD crystal formation and deposition involves enhanced ecto-NTPPPH activity resulting from vesicles that play a role in normal bone calcification. Studies have confirmed that vesicles derived from collagenase digestion of articular cartilage are selectively rich in NTPPPH activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These NTPPPH-rich vesicles promote the formation of a calcium- and PPi-containing mineral that resembles CPPD crystals when incubated with ATP. Such vesicles are similar to the matrix vesicles of normal epiphyseal cartilage. Among the isozymes with ecto-NTPPPH activity, the plasma cell membrane protein PC-1, when over-expressed through gene transfer to cultured chondrocytes, is associated with increased chondrocyte apoptosis and matrix calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second line of evidence confirming enhanced PPi production in CPPD involves findings in another mouse disorder, murine progressive ankylosis, in which homozygous nonsense mutation in the ank gene results in reduced extracellular PPi levels and extensive peripheral and axial skeleton ankylosis with basic calcium phosphate-containing material [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/15\">",
"     15",
"    </a>",
"    ]. The ank gene product is a transmembrane protein, strongly expressed in chondrocytes, which serves either as a PPi transporter or as a regulator of a channel transporting PPi or a PPi precursor. Expression of the normal ank allele in transgenic mutant mice prevents the phenotypic and physiological defects and the overexpression of the normal ank allele in cells from mutant mice results in excessive extracellular PPi levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/15\">",
"     15",
"    </a>",
"    ], suggesting that circumstances enhancing activity of the ank gene could promote CPPD crystal formation and deposition.",
"   </p>",
"   <p>",
"    Confirmation of a role of the human homolog of the ank gene (ANKH) in familial CPPD disease has been provided by the finding in five pedigrees of segregation of a mutant gene for this putative PPi transport channel with the chondrocalcinosis phenotype and by the subsequent identification of the precise mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. In addition, mutations in or just upstream of the chromosome 5p locus of ANKH have also been identified in individuals with idiopathic or sporadic CPPD deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of CPPD crystals in disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive causal role of CPPD crystals in all of the clinical manifestations with which deposition is associated has not been established; this is particularly the case with the degenerative, noninflammatory manifestations of CPPD arthropathy (pseudo-osteoarthritis). Nevertheless, compelling evidence for a role of the CPPD crystal in acute and subacute joint inflammation is provided by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are striking similarities in the pathogenetic mechanisms and clinical appearances of urate and CPPD crystal-induced arthritis (acute gout and pseudogout, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/21\">",
"       21",
"      </a>",
"      ]. Of particular note is the shared capacity to induce NALP3-dependent inflammasome assembly and activation in synovial mononuclear phagocytes and neutrophils, an action that is associated with IL-1 precursor processing and release of the pro-inflammatory cytokine IL-1beta [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The apparent biologic consequences of the interaction of CPPD crystals with phagocytic cells (which include mitogenic activation and the release of proinflammatory cytokines) provide a potential basis for the more subacute inflammatory synovitis seen in the pseudo-rheumatoid pattern of CPPD arthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An etiologic or an amplifying role for CPPD crystals in the destructive changes in pseudo-osteoarthritis appears highly likely because, first, the degenerative arthritis accompanying CPPD crystal deposition frequently involves joints like the metacarpophalangeal and wrist joints, which are commonly spared in classical osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/4\">",
"       4",
"      </a>",
"      ], and second, chondrocalcinosis appears to be a primary determinant of the rate of radiographically-determined joint deterioration in this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoremission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks of pseudogout are characteristically self-limited. Although possible mechanisms for ameliorating inflammation due to CPPD crystals have been suggested, a generally accepted explanation is lacking. Phagocytosis and dissolution of crystals may play a role, but animal models indicate that inflammation abates while crystals are still present in tissue fluid.",
"   </p>",
"   <p>",
"    Adhesion of components of extracellular fluid or plasma to crystals may decrease their inflammatory potential. As an example, addition of lipoproteins to CPPD crystals reduces their ability to provoke neutrophil phagocytosis and cell lysis in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/25\">",
"     25",
"    </a>",
"    ]. In an experimental model, the local low-density lipoprotein (LDL) concentration rose within hours after instillation of CPPD crystals in association with decreasing inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of CPPD crystal deposition disease are idiopathic, joint trauma, familial chondrocalcinosis, and a variety of metabolic and endocrine disorders are associated with or may cause the illness, particularly among the young [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Joint trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint trauma (including prior joint surgery) is a demonstrated risk factor for the development of subsequent CPPD crystal deposition. As a result, a history of trauma should be sought in younger patients in whom clinical or radiographic evidence of CPPD crystal deposition is found [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Familial chondrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial chondrocalcinosis is typically manifested by an autosomal dominant inheritance and by the occurrence of clinical events earlier in life than is commonly observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/1\">",
"     1",
"    </a>",
"    ]. As noted above, in five pedigrees of familial CPPD disease, the presence of chondrocalcinosis segregated with a mutant gene for ANKH, a transmembrane protein that is clearly involved in PPi transport [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical literature review relating metabolic and endocrine diseases with calcium pyrophosphate crystal deposition disease led to the conclusion that hemochromatosis is the",
"    <strong>",
"     only",
"    </strong>",
"    disease clearly associated with the full spectrum of CPPD crystal-related joint disease (ie, pseudogout, chondrocalcinosis, and chronic arthropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"     27",
"    </a>",
"    ]. The importance of iron accumulation in joint tissues in this setting is supported by reports of CPPD crystal deposition in patients with transfusion hemosiderosis and hemophilic arthritis. However, the lack of an unduly high frequency of chondrocalcinosis in patients with rheumatoid arthritis despite considerable iron accumulation in the synovium suggests that other factors must be responsible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other associated disorders and precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of metabolic and endocrine disorders other than hemochromatosis are associated with CPPD crystal deposition. Clinical or radiographic evidence for CPPD crystal deposition disease, therefore, warrants exclusion of these disorders, particularly among younger individuals (",
"    <a class=\"graphic graphic_table graphicRef65287 \" href=\"UTD.htm?23/26/23979\">",
"     table 1",
"    </a>",
"    ). Although a cause-and-effect relationship is unproven (and, in some instances, a chance association is possible), the importance of recognizing these associations lies in the opportunity to identify and to treat a significant illness such as hemochromatosis or hyperparathyroidism prior to the expression of additional clinical manifestations of these disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperparathyroidism, hypomagnesemia, and hypophosphatasia are associated with both chondrocalcinosis and pseudogout but are not clearly associated with CPPD arthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"       \"Clinical manifestations of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gitelman's syndrome, an inherited renal tubular disorder resulting in hypokalemia and hypomagnesemia, has been associated with both chondrocalcinosis and pseudogout [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gout, hypothyroidism, X-linked hypophosphatemic rickets, and familial hypocalciuric hypercalcemia are probably associated with CPPD crystal deposition disease, but the relationship is less clearly demonstrable [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associations of acromegaly, diabetes mellitus, Wilson's disease, and ochronosis with chondrocalcinosis are doubtful or unlikely [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isolated, as well as recurrent, episodes of acute pseudogout have been associated with joint injection of hyaluronate [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The mechanism of action is unknown; it has been speculated that phosphate present in the hyaluronate preparation may lower intraarticular calcium concentrations, leading to crystal shedding. A similar phenomenon has been described with hypocalcemia following parathyroidectomy or after intravenous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6375/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"       \"Patient information: Pseudogout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"       \"Patient information: Pseudogout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27474517\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium pyrophosphate crystal deposition disease is a disease of older adults, and radiographic surveys demonstrate an age-related increase in the prevalence of articular chondrocalcinosis. There is no major sex predominance, although attacks of acute calcium pyrophosphate dihydrate (CPPD) arthritis, which are often termed pseudogout, occur more frequently in men, while pseudo-osteoarthritis is more common in women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CPPD crystal formation is initiated in cartilage located near the surface of chondrocytes. The disorder is generally thought to be associated with excessive cartilage pyrophosphate (PPi) production, leading to local calcium pyrophosphate supersaturation and CPPD crystal formation or deposition, although aberrations in both mineral and organic phase metabolism are probably variably involved in CPPD crystal deposition disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is compelling evidence for a role of the CPPD crystal in acute and subacute joint inflammation, although a definitive causal role of CPPD crystals in all of the clinical manifestations with which deposition is associated, particularly the noninflammatory changes, has not been established. The typically self-limited nature of acute attacks of pseudogout is not well-understood. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of CPPD crystals in disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Autoremission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of CPPD crystal deposition disease are idiopathic, but joint trauma, including prior joint surgery; familial chondrocalcinosis; and a variety of metabolic and endocrine disorders, including hemochromatosis, are associated with or may cause the illness, particularly among the young (",
"      <a class=\"graphic graphic_table graphicRef65287 \" href=\"UTD.htm?23/26/23979\">",
"       table 1",
"      </a>",
"      ). Hemochromatosis is the only disorder associated with the full spectrum of CPPD-related diseases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology and disease associations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Joint trauma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Familial chondrocalcinosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Hemochromatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperparathyroidism, hypomagnesemia, and hypophosphatasia are associated with both chondrocalcinosis and pseudogout but are not clearly associated with CPPD arthropathy; Gitelman's syndrome, an inherited renal tubular disorder, is associated with both chondrocalcinosis and pseudogout. Other reported associations are less certain (eg, gout, hypothyroidism, X-linked hypophosphatemic rickets, and familial hypocalciuric hypercalcemia) or doubtful. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other associated disorders and precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rosenthal AK. Pseudogout: Presentation, natural history, and associated conditions. In: Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor &amp; Francis Group, New York 2006. p.99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/2\">",
"      Ellman MH, Levin B. Chondrocalcinosis in elderly persons. Arthritis Rheum 1975; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/3\">",
"      Memin Y, Monville C, Ryckewaert A. [Articular chondrocalcinosis after 80 years of age]. Rev Rhum Mal Osteoartic 1978; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/4\">",
"      Wilkins E, Dieppe P, Maddison P, Evison G. Osteoarthritis and articular chondrocalcinosis in the elderly. Ann Rheum Dis 1983; 42:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/5\">",
"      O'Duffy JD. Clinical studies of acute pseudogout attacks: comments on prevalence, predispositions, and treatment. Arthritis Rheum 1976; 19 Suppl 3:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/6\">",
"      Dieppe PA, Alexander GJ, Jones HE, et al. Pyrophosphate arthropathy: a clinical and radiological study of 105 cases. Ann Rheum Dis 1982; 41:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/7\">",
"      Fam AG, Topp JR, Stein HB, Little AH. Clinical and roentgenographic aspects of pseudogout: a study of 50 cases and a review. Can Med Assoc J 1981; 124:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/8\">",
"      Rachow JW, Ryan LM. Adenosine triphosphate pyrophosphohydrolase and neutral inorganic pyrophosphatase in pathologic joint fluids. Elevated pyrophosphohydrolase in calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 1985; 28:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/9\">",
"      Tenenbaum J, Muniz O, Schumacher HR, et al. Comparison of phosphohydrolase activities from articular cartilage in calcium pyrophosphate deposition disease and primary osteoarthritis. Arthritis Rheum 1981; 24:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/10\">",
"      Ryan LM, Wortmann RL, Karas B, McCarty DJ Jr. Cartilage nucleoside triphosphate (NTP) pyrophosphohydrolase. I. Identification as an ecto-enzyme. Arthritis Rheum 1984; 27:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/11\">",
"      Okawa A, Nakamura I, Goto S, et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/12\">",
"      Siegel SA, Hummel CF, Carty RP. The role of nucleoside triphosphate pyrophosphohydrolase in in vitro nucleoside triphosphate-dependent matrix vesicle calcification. J Biol Chem 1983; 258:8601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/13\">",
"      Derfus BA, Rachow JW, Mandel NS, et al. Articular cartilage vesicles generate calcium pyrophosphate dihydrate-like crystals in vitro. Arthritis Rheum 1992; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/14\">",
"      Johnson K, Pritzker K, Goding J, Terkeltaub R. The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles. J Rheumatol 2001; 28:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/15\">",
"      Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/16\">",
"      Williams CJ, Zhang Y, Timms A, et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002; 71:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/17\">",
"      Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/18\">",
"      Hughes AE, McGibbon D, Woodward E, et al. Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995; 4:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/19\">",
"      Andrew LJ, Brancolini V, de la Pena LS, et al. Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Hum Genet 1999; 64:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/20\">",
"      Zhang Y, Johnson K, Russell RG, et al. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum 2005; 52:1110.",
"     </a>",
"    </li>",
"    <li>",
"     Dalbeth N, Haskard DO. Pathophysiology of crystal-induced arthritis. In: Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor &amp; Francis Group, New York 2006. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/22\">",
"      Martinon F, P&eacute;trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/23\">",
"      Cheung HS, Story MT, McCarty DJ. Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystals on cultured mammalian cells. Arthritis Rheum 1984; 27:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/24\">",
"      Ledingham J, Regan M, Jones A, Doherty M. Factors affecting radiographic progression of knee osteoarthritis. Ann Rheum Dis 1995; 54:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/25\">",
"      Burt HM, Jackson JK, Rowell J. Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals. J Rheumatol 1989; 16:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/26\">",
"      Kumagai Y, Watanabe W, Kobayashi A, et al. Inhibitory effect of low density lipoprotein on the inflammation-inducing activity of calcium pyrophosphate dihydrate crystals. J Rheumatol 2001; 28:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/27\">",
"      Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/28\">",
"      Doherty M, Watt I, Dieppe PA. Localised chondrocalcinosis in post-meniscectomy knees. Lancet 1982; 1:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/29\">",
"      Lind&eacute;n B, Nilsson BE. Chondrocalcinosis following osteochondritis dissecans in the femur condyles. Clin Orthop Relat Res 1978; :223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/30\">",
"      Punzi L, Cal&ograve; L, Schiavon F, et al. Chondrocalcinosis is a feature of Gitelman's variant of Bartter's syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. Rev Rhum Engl Ed 1998; 65:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/31\">",
"      Cobeta-Garcia JC, Gasc&oacute;n A, Iglesias E, Estopi&ntilde;&aacute;n V. Chondrocalcinosis and Gitelman's syndrome. A new association? Ann Rheum Dis 1998; 57:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/32\">",
"      Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum 1998; 41:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/33\">",
"      Disla E, Infante R, Fahmy A, et al. Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Arthritis Rheum 1999; 42:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/34\">",
"      Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989; 106:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6375/abstract/35\">",
"      Malnick SD, Ariel-Ronen S, Evron E, Sthoeger ZM. Acute pseudogout as a complication of pamidronate. Ann Pharmacother 1997; 31:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1665 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6375=[""].join("\n");
var outline_f6_14_6375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27474517\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of CPPD crystals in disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoremission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Joint trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Familial chondrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other associated disorders and precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27474517\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23979\" title=\"table 1\">",
"      Diseases associated with CPPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=related_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=related_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18134?source=related_link\">",
"      Treatment of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6376="Pathogenesis of sarcoidosis";
var content_f6_14_6376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Andrew Fontenot, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6376/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/14/6376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem disorder of unknown etiology characterized by the accumulation of T lymphocytes, mononuclear phagocytes, and noncaseating granulomas in involved tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The lungs are affected in approximately 90 percent of patients, and pulmonary disease accounts for the majority of the morbidity and mortality associated with this disease. Other tissues commonly involved include the skin, eyes, and lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef76046 \" href=\"UTD.htm?26/16/26892\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial lesion within the pulmonary system is a CD4+ T cell alveolitis, followed by the development of noncaseating granulomata [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. The granulomas have a tightly packed central area composed of macrophages, epithelioid cells, and multinucleated giant cells surrounded by lymphocytes, monocytes, mast cells, and fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/7\">",
"     7",
"    </a>",
"    ]. Within the lung, granulomas tend to occur in a bronchocentric fashion that can lead to either obstructive or restrictive pulmonary physiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H34#H34\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Pulmonary function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sarcoid granuloma can resolve without sequelae or undergo obliterative fibrosis, with the resultant development of interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. The presence of granulomatous inflammation is thought to result from an exaggerated cell-mediated immune response to one or more unidentified antigen(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSSIBLE ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in our knowledge of the immunopathogenesis of sarcoidosis, the antigenic stimulus that initiates the disease process remains elusive. The multicenter NIH-funded ACCESS case-control study of over 700 patients and nearly 30,000 relatives has been completed, and no single etiologic agent or genetic locus was clearly implicated in the pathogenesis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Several possible associations have been investigated, as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Occupational and environmental exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that sarcoidosis is associated with several occupational and environmental exposures. However, only beryllium and its salts have been shown to produce granulomata that are similar to that seen in sarcoidosis. Despite intensive efforts, studies have largely failed to identify an external agent or agents responsible for sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series suggested that exposure to World Trade Center (WTC) dust during the collapse, rescue, or recovery was associated with an increased incidence of sarcoidosis-like granulomatous pulmonary disease during the five years following the disaster [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/13\">",
"     13",
"    </a>",
"    ]. The series reported 26 patients who had pathologic evidence of new onset sarcoidosis following WTC dust exposure. The estimated annual incidence rate was 86 cases per 100,000 population during the first year after the WTC collapse and 22 cases per 100,000 population during the next four years. In comparison, the estimated annual incidence rate was 15 cases per 100,000 during the 15 years prior to the disaster. Eighteen of the 26 patients (69 percent) also developed findings consistent with asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Kveim-Siltzbach reagent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1961, Siltzbach noted that approximately 70 percent of patients with early sarcoidosis developed granulomatous inflammation four to six weeks after the intradermal injection of the Kveim-Siltzbach reagent (consisting of homogenates of human sarcoid tissue) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/14\">",
"     14",
"    </a>",
"    ]. However, multiple studies of the components of the Kveim-Siltzbach reagent have failed to identify a responsible antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infectious agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous microorganisms, most notably mycobacteria and propionibacteria, have been implicated as possible etiologic agents of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/15-25\">",
"     15-25",
"    </a>",
"    ]. In addition, the apparent transmission of sarcoidosis following cardiac and bone marrow transplantation has also provided support for an infectious etiologic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic similarity of sarcoidosis to Mycobacterium tuberculosis infection led to the extensive evaluation of this organism as a possible etiologic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/15\">",
"     15",
"    </a>",
"    ]. A number of studies, including those using hybridization techniques and the polymerase chain reaction, found evidence of M. tuberculosis in sarcoid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; however, these findings have not been confirmed in other reports using similar techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One intriguing study demonstrated growth of acid-fast cell wall-deficient forms of bacteria (L forms) from the blood of 19 of 20 patients with sarcoidosis but none of 20 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/23\">",
"     23",
"    </a>",
"    ]. These isolates stained positively with an antibody raised against M. tuberculosis whole cell antigen. However, whether these organisms are etiologically important in sarcoidosis is currently unknown. A large case-control study found no difference in the number of cell wall-deficient mycobacterial forms in blood cultures from patients with and without sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mycobacterial antigen, Mycobacterium tuberculosis catalase-peroxidase (mKatG), was found in most sarcoidosis tissue samples examined, but not in control tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/29\">",
"     29",
"    </a>",
"    ]. In a related study, an increased number of T cells reactive to mKatG were found in peripheral blood and bronchoalveolar lavage fluid from patients with sarcoidosis, compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/30\">",
"     30",
"    </a>",
"    ]. In sarcoidosis, the mKatG-reactive T cells preferentially accumulated in the lung, indicating a compartmentalized response and are consistent with the profile expected for a pathogenic antigen.",
"   </p>",
"   <p>",
"    A study from Japan reported detection of Propionibacterium acnes in 12 of 15 patients using the polymerase chain reaction; positive results, but with many fewer genome copies, were also found in 2 of 15 patients with tuberculosis and in 3 of 15 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/22\">",
"     22",
"    </a>",
"    ]. All three patients with sarcoidosis who did not have detectable Propionibacterium acnes did have another species of Propionibacterium (P. granulosum) found by the polymerase chain reaction. Propionibacterium acnes may act to \"prime\" the immune system prior to the development of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/31\">",
"     31",
"    </a>",
"    ]. Although this theory is intriguing, it is not yet known whether there is any causal relationship between Propionibacterium species and sarcoidosis.",
"   </p>",
"   <p>",
"    In one report, human herpes virus (HHV)-8 DNA sequences were detected in lung biopsies in eight of eight sarcoid patients compared to 3 of 56 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/32\">",
"     32",
"    </a>",
"    ]. However, subsequent studies have not confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Major histocompatibility complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occasional occurrence of sarcoidosis in more than one member of a family suggests the possibility of a genetic contribution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. An ambitious case-control study of 706 patients and over 27,000 first- and second-degree relatives confirmed that first-degree relatives are at increased risk for developing sarcoidosis (odds ratio 4.7, 95% CI 2.3 to 9.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/9\">",
"     9",
"    </a>",
"    ]. This risk was greater for relatives of Caucasian patients than for those of African-American descent (OR 18.0 versus 2.8).",
"   </p>",
"   <p>",
"    Genetic susceptibility to sarcoidosis has been most closely linked with antigens of the major histocompatibility complex (MHC) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, the pattern varies depending upon the ethnic and racial makeup of the population studied, and the associations are relatively weak [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In ACCESS, the HLA-DR allele,",
"    <em>",
"     DRB1*1101",
"    </em>",
"    , was significantly associated with sarcoidosis development in both African-Americans and Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/45\">",
"     45",
"    </a>",
"    ]. This study and others suggest that the genetic background of the individual may account for the clinical heterogeneity of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. For example, in Scandinavian subjects with acute sarcoidosis (L&ouml;fgren&rsquo;s syndrome) and other white populations with sarcoidosis, an association between the presence of",
"    <em>",
"     HLA-DRB1*0301",
"    </em>",
"    and remitting sarcoidosis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome wide linkage and association studies have identified some additional genes that may be associated with increased susceptibility to sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. These include the butyrophilin-like 2 gene (BTNL2) and annexin A11 (ANXA11) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Other studies have suggested an association between the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of sarcoidosis and angiotensin converting enzyme genotypes in certain subgroups of patients, including African-Americans and Finns [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene expression analysis has been used to identify networks of genes that may be involved in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. As an example, gene array studies on lung tissue from healthy controls and patients with active sarcoidosis identified over-expression of two gene networks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/58\">",
"     58",
"    </a>",
"    ]. One network includes genes associated with Th1 type antigen responses (ie, interleukin [IL] 7, IL15, the transcription factor family STAT1, and lymphocyte chemoattractant genes); the second network includes the proteases MMP-12 and ADAMDEC1. It is thought that these proteases participate in lung remodeling, although their exact role is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     T cell abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical staining of sarcoid granulomas has demonstrated that the majority of lymphocytes within the granuloma are CD4+ T cells. However, the periphery of the granuloma is composed of CD4+ as well as CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/3,60\">",
"     3,60",
"    </a>",
"    ]. Since the cells obtained with bronchoalveolar lavage (BAL) in sarcoidosis adequately reflect the degree of alveolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], BAL has been used to assess the cellular populations present in the lower respiratory tract.",
"   </p>",
"   <p>",
"    Examination of BAL fluid from patients with sarcoidosis may demonstrate dramatic increases in cellularity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2,63,64\">",
"     2,63,64",
"    </a>",
"    ]. The cell count differential of BAL fluid demonstrates a lymphocytic pleocytosis, with a predominance of CD4+ T cells as compared to peripheral blood or to lung lymphocytes obtained from healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2,63,64\">",
"     2,63,64",
"    </a>",
"    ]. These CD4+ T cells bear surface markers of previous activation and have the ability to spontaneously secrete interleukin-2, interferon gamma, and other cytokines characteristic of the Th1 phenotype. Thus, CD4+ T cells may be important in initiating and perpetuating the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/2,6,63,65-67\">",
"     2,6,63,65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of cytokines in the immune system\", section on 'T cell subsets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison to the BAL findings, the peripheral blood of patients with pulmonary sarcoidosis shows a T cell lymphopenia, a decrease in the number of CD4+ T cells, and a decreased",
"    <span class=\"nowrap\">",
"     CD4+/CD8+",
"    </span>",
"    T cell ratio. One study noted that a specific subset of CD4+ T cells with immunoregulatory properties, known as CD1d-restricted natural killer cells (CD1d-rNKT cells), are profoundly decreased or absent in both the peripheral blood and BAL fluid of patients with sarcoidosis, regardless of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/68\">",
"     68",
"    </a>",
"    ]. A decreased in vitro response to T cell mitogens also occurs, and a hypergammaglobulinemia is observed secondary to generalized B cell hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     T cell receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the intimate association between CD4+ T cells and the pathogenesis of sarcoidosis, numerous groups have investigated the T cell antigen receptor (TCR) (",
"    <a class=\"graphic graphic_figure graphicRef53512 \" href=\"UTD.htm?37/38/38499\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/63,65-67,69,70\">",
"     63,65-67,69,70",
"    </a>",
"    ]. The TCR is composed of an alpha and a beta chain and is responsible for recognizing processed peptide antigens in the context of class I or II MHC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/71\">",
"     71",
"    </a>",
"    ]. The enormous diversity of the TCR is acquired through somatic rearrangement of the variable (V), diversity (D), and joining (J) segments along with the random addition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deletion of N-region nucleotides to form a unique V(D)J region (",
"    <a class=\"graphic graphic_figure graphicRef53335 \" href=\"UTD.htm?7/46/7919\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies of the TCR Vbeta repertoire in patients with active sarcoidosis has demonstrated bias in certain TCR Vbeta subsets, including Vbeta2, Vbeta8, Vbeta12, and Valpha2.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/63,65-67,69,70\">",
"     63,65-67,69,70",
"    </a>",
"    ]. In addition, different Vbeta gene segments are expanded in different individuals. A possible explanation for this observation is that the HLA class II type might select the predominant Vbeta expressed among different patients. Some studies, for example, have found an increased number of Valpha2.3+ T cells in patients with sarcoidosis who express HLA-DR3. Another explanation for the different Vbetas is that different epitopes or antigens are being recognized at the site of disease activity.",
"   </p>",
"   <p>",
"    Junctional region sequencing has demonstrated that the preferential expression of specific Vbeta regions in the bronchoalveolar lavage (BAL) is oligoclonal in nature, suggesting conventional antigenic (Ag) stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/63,65-67\">",
"     63,65-67",
"    </a>",
"    ]. This is in contrast to superantigenic stimulation, which results in polyclonal expansion of a particular Vbeta gene segment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/72\">",
"     72",
"    </a>",
"    ]. Interestingly, the Kveim reaction site is also characterized by a limited TCR Vbeta repertoire consistent with an Ag-driven immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/66\">",
"     66",
"    </a>",
"    ]. Taken together, these observations suggest that the activated, disease-specific CD4+ T cell clones accumulate at sites of disease activity in response to unknown sarcoid antigen(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The granulomatous response in sarcoidosis is characterized by a highly-polarized T helper 1 (Th1) cytokine response. After T cell recognition of antigen(s), CD4+ T cells secrete Th1-type cytokines such as interleukin (IL)-2, interferon (IFN) gamma, and tumor necrosis factor (TNF) alpha. The release of IFN gamma and TNF alpha promotes macrophage accumulation, activation, and aggregation, resulting in the development of granulomatous inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link&amp;anchor=H6#H6\">",
"     \"T helper subsets: Differentiation and role in disease\", section on 'Cytokine profiles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IL-2 is important in expanding the activated lymphocyte population within the lung, either by in situ proliferation or by cellular redistribution from the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, IL-2 is involved in the differentiation of B cells with the resultant development of hypergammaglobulinemia. Activated CD4+ T cells possess IL-2 receptors and have the ability to proliferate in vitro in the presence of IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/63\">",
"     63",
"    </a>",
"    ]. IL-15 is produced by macrophages and cooperates with IL-2 in initiating cell-mediated immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/73\">",
"     73",
"    </a>",
"    ]. IL-15 shares several biologic functions with IL-2, including stimulating the proliferation of T cells and B cells. Even though IL-15 and IL-2 are structurally dissimilar, the effects of IL-15 occur through the IL-2 receptor system and may trigger the proliferation of CD4+ T cells in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-12, IL-18 and IL-27 promote Th1 immune responses and are increased in the lungs of sarcoidosis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. These cytokines act synergistically to stimulate IFN-gamma production from CD4+ Th1 T cells. A recent study identified Th17 cells in blood and BAL fluid of patients with active sarcoidosis, suggesting that IL-17-expressing cells may play a role in the alveolitis phase of disease, potentially leading to fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated levels of IL-6 and IL-8 have been identified in the BAL fluid of patients with active pulmonary sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. IL-6 is produced by macrophages, fibroblasts, and T and B cells, and is a signal for T and B cell proliferation. IL-8 is a potent neutrophil chemotactic factor released from macrophages. A positive correlation existed between IL-6 and IL-8 levels in the BAL fluid and BAL neutrophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/77\">",
"     77",
"    </a>",
"    ]. An association has previously been noted between BAL neutrophilia and a worse prognosis in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/78\">",
"     78",
"    </a>",
"    ]. Thus, IL-6 and IL-8 may be important in modifying the disease process.",
"   </p>",
"   <p>",
"    Subsequently, the Th1 type profile shifts to a Th2 type profile with the release of Th2 cytokines, including IL-4, stimulating the production of extracellular matrix proteins, chemoattractants for fibroblasts, and evolution to fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/3\">",
"     3",
"    </a>",
"    ]. Cytokines such as IL-16, IL-8, and IP10 are involved in the recruitment of neutrophils, eosinophils, macrophages, and T lymphocytes, and in the development of granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is well known to be associated with abnormalities in calcium regulation in some patients, and a possible association with common variable immunodeficiency has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abnormal calcium homeostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated pulmonary macrophages in sarcoidosis also produce calcitriol, the active form of vitamin D. The importance of calcitriol in the pathogenesis of sarcoidosis is not known, but it is responsible for the hypercalciuria and hypercalcemia that are frequently seen. In addition, vitamin D receptor polymorphisms have been reported in Japanese patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1996 series found eight cases of common variable immunodeficiency (CVID) out of 80 patients with sarcoidosis and noted that 22 other cases had been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/80\">",
"     80",
"    </a>",
"    ]. The possible presence of this disorder should be suspected in patients with sarcoidosis who have recurrent infections and do not have hypergammaglobulinemia.",
"   </p>",
"   <p>",
"    The mechanism of the apparent relation between these disorders is not known. In view of the above discussion, at least two possibilities can be proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CVID predisposes to an infectious agent that is responsible for sarcoidosis",
"     </li>",
"     <li>",
"      Both disorders are associated with a similar T cell abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       \"Patient information: Sarcoidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       \"Patient information: Sarcoidosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the advances in our knowledge of the immunopathogenesis of sarcoidosis, the etiology remains a mystery. Studies investigating the T cell antigen receptor (TCR) Vbeta repertoire have demonstrated oligoclonality of the junctional region consistent with conventional antigenic stimulation. However, no single etiologic agent or genetic locus has been clearly implicated in the pathogenesis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6376/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/1\">",
"      Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/2\">",
"      Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/3\">",
"      Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000; 12:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/4\">",
"      Hunninghake GW, Garrett KC, Richerson HB, et al. Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis 1984; 130:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/5\">",
"      Hunninghake GW, Gadek JE. Immunological aspects of chronic non-infectious pulmonary diseases of the lower respiratory tract in man. Clin Immunol Rev 1981; 1:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/6\">",
"      NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med 1981; 94:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/7\">",
"      Soler P, Basset F. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann N Y Acad Sci 1976; 278:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/8\">",
"      Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/9\">",
"      Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/10\">",
"      Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/11\">",
"      Iannuzzi MC. Advances in the genetics of sarcoidosis. Proc Am Thorac Soc 2007; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/12\">",
"      Moller DR, Chen ES. What causes sarcoidosis? Curr Opin Pulm Med 2002; 8:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/13\">",
"      Izbicki G, Chavko R, Banauch GI, et al. World Trade Center \"sarcoid-like\" granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/14\">",
"      SILTZBACH LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA 1961; 178:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/15\">",
"      Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis 1995; 12:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/16\">",
"      Mitchell IC, Turk JL, Mitchell DN. Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Lancet 1992; 339:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/17\">",
"      Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/18\">",
"      Bocart D, Lecossier D, De Lassence A, et al. A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Am Rev Respir Dis 1992; 145:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/19\">",
"      Richter E, Greinert U, Kirsten D, et al. Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med 1996; 153:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/20\">",
"      Vokurka M, Lecossier D, du Bois RM, et al. Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997; 156:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/21\">",
"      Wilsher ML, Menzies RE, Croxson MC. Mycobacterium tuberculosis DNA in tissues affected by sarcoidosis. Thorax 1998; 53:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/22\">",
"      Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999; 354:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/23\">",
"      Almenoff PL, Johnson A, Lesser M, Mattman LH. Growth of acid fast L forms from the blood of patients with sarcoidosis. Thorax 1996; 51:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/24\">",
"      Brown ST, Brett I, Almenoff PL, et al. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003; 123:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/25\">",
"      Planck A, Eklund A, Grunewald J, Vene S. No serological evidence of Rickettsia helvetica infection in Scandinavian sarcoidosis patients. Eur Respir J 2004; 24:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/26\">",
"      Burke WM, Keogh A, Maloney PJ, et al. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990; 336:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/27\">",
"      Heyll A, Meckenstock G, Aul C, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/28\">",
"      Bhagat R, Rizzieri DA, Vredenburgh JJ, et al. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? Chest 2004; 126:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/29\">",
"      Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/30\">",
"      Chen ES, Wahlstr&ouml;m J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181:8784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/31\">",
"      Nishiwaki T, Yoneyama H, Eishi Y, et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol 2004; 165:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/32\">",
"      Di Alberti L, Piattelli A, Artese L, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet 1997; 350:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/33\">",
"      B&eacute;lec L, Mohamed AS, Lechapt-Zalcman E, et al. Lack of HHV-8 DNA sequences in sarcoid tissues of French patients. Chest 1998; 114:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/34\">",
"      Maeda H, Niimi T, Sato S, et al. Human herpesvirus 8 is not associated with sarcoidosis in Japanese patients. Chest 2000; 118:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/35\">",
"      Rybicki BA, Harrington D, Major M, et al. Heterogeneity of familial risk in sarcoidosis. Genet Epidemiol 1996; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/36\">",
"      Brennan NJ, Crean P, Long JP, Fitzgerald MX. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984; 39:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/37\">",
"      Rybicki BA, Kirkey KL, Major M, et al. Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol 2001; 153:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/38\">",
"      Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008; 63:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/39\">",
"      M&uuml;ller-Quernheim J, Sch&uuml;rmann M, Hofmann S, et al. Genetics of sarcoidosis. Clin Chest Med 2008; 29:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/40\">",
"      Chen ES, Moller DR, Medscape. Sarcoidosis--scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/41\">",
"      Rybicki BA, Maliarik MJ, Poisson LM, et al. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003; 167:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/42\">",
"      Ina Y, Takada K, Yamamoto M, et al. HLA and sarcoidosis in the Japanese. Chest 1989; 95:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/43\">",
"      Odum N, Milman N, Jakobsen BK, et al. HLA class II (DR, DQ, DP) in patients with sarcoidosis: evidence of an increased frequency of DRw6. Exp Clin Immunogenet 1991; 8:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/44\">",
"      Martinetti M, Tinelli C, Kolek V, et al. \"The sarcoidosis map\": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/45\">",
"      Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/46\">",
"      Mehra NK, Bovornkitti S. HLA and sarcoidosis. Sarcoidosis 1988; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/47\">",
"      Berlin M, Fogdell-Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/48\">",
"      Grunewald J. Genetics of sarcoidosis. Curr Opin Pulm Med 2008; 14:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/49\">",
"      Pabst S, Karpushova A, Diaz-Lacava A, et al. VEGF gene haplotypes are associated with sarcoidosis. Chest 2010; 137:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/50\">",
"      Fischer A, Nothnagel M, Sch&uuml;rmann M, et al. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered biallelic markers. Chest 2010; 138:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/51\">",
"      Fischer A, Schmid B, Ellinghaus D, et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Respir Crit Care Med 2012; 186:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/52\">",
"      Hofmann S, Fischer A, Nothnagel M, et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. Eur Respir J 2013; 41:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/53\">",
"      Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/54\">",
"      Hofmann S, Franke A, Fischer A, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008; 40:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/55\">",
"      Li Y, Pabst S, Kubisch C, et al. First independent replication study confirms the strong genetic association of ANXA11 with sarcoidosis. Thorax 2010; 65:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/56\">",
"      Maliarik MJ, Rybicki BA, Malvitz E, et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998; 158:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/57\">",
"      Pietinalho A, Furuya K, Yamaguchi E, et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/58\">",
"      Crouser ED, Culver DA, Knox KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/59\">",
"      Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010; 181:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/60\">",
"      Semenzato G, Pezzutto A, Chilosi M, Pizzolo G. Redistribution of T lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 1982; 306:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/61\">",
"      Semenzato G, Chilosi M, Ossi E, et al. Bronchoalveolar lavage and lung histology. Comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985; 132:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/62\">",
"      Campbell DA, Poulter LW, du Bois RM. Immunocompetent cells in bronchoalveolar lavage reflect the cell populations in transbronchial biopsies in pulmonary sarcoidosis. Am Rev Respir Dis 1985; 132:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/63\">",
"      Forrester JM, Wang Y, Ricalton N, et al. TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. J Immunol 1994; 153:4291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/64\">",
"      Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/65\">",
"      Forman JD, Klein JT, Silver RF, et al. Selective activation and accumulation of oligoclonal V beta-specific T cells in active pulmonary sarcoidosis. J Clin Invest 1994; 94:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/66\">",
"      Klein JT, Horn TD, Forman JD, et al. Selection of oligoclonal V beta-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol 1995; 154:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/67\">",
"      Moller DR, Konishi K, Kirby M, et al. Bias toward use of a specific T cell receptor beta-chain variable region in a subgroup of individuals with sarcoidosis. J Clin Invest 1988; 82:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/68\">",
"      Ho LP, Urban BC, Thickett DR, et al. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005; 365:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/69\">",
"      Grunewald J, Olerup O, Persson U, et al. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci U S A 1994; 91:4965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/70\">",
"      Grunewald J, Janson CH, Eklund A, et al. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol 1992; 22:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/71\">",
"      Marrack P, Kappler J. The T cell receptor. Science 1987; 238:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/72\">",
"      Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/73\">",
"      Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/74\">",
"      Greene CM, Meachery G, Taggart CC, et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000; 165:4718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/75\">",
"      Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001; 166:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/76\">",
"      Larousserie F, Pflanz S, Coulomb-L'Hermin&eacute; A, et al. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/77\">",
"      Girgis RE, Basha MA, Maliarik M, et al. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 152:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/78\">",
"      Roth C, Huchon GJ, Arnoux A, et al. Bronchoalveolar cells in advanced pulmonary sarcoidosis. Am Rev Respir Dis 1981; 124:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/79\">",
"      Niimi T, Tomita H, Sato S, et al. Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med 1999; 160:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/80\">",
"      Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) 1996; 75:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/81\">",
"      Sutor G, Fabel H. Sarcoidosis and common variable immunodeficiency. A case of a malignant course of sarcoidosis in conjunction with severe impairment of the cellular and humoral immune system. Respiration 2000; 67:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6376/abstract/82\">",
"      Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997; 127:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4365 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6376=[""].join("\n");
var outline_f6_14_6376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSSIBLE ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Occupational and environmental exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Kveim-Siltzbach reagent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infectious agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Major histocompatibility complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      T cell abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - T cell receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abnormal calcium homeostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4365|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/38/38499\" title=\"figure 1\">",
"      HLA TCR complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/46/7919\" title=\"figure 2\">",
"      Arrangement of T cell receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4365|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/16/26892\" title=\"table 1\">",
"      Sarcoid organ involvement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6377="Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease";
var content_f6_14_6377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Ann L Parke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6377/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/14/6377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain gastrointestinal diseases can produce extraintestinal manifestations. A common example of this phenomenon occurs in patients with inflammatory bowel disease (IBD) who may develop arthritis, iritis, skin disease (eg, erythema nodosum), vasculitis, and hemolytic anaemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In one series, 36 percent of patients with ulcerative colitis or Crohn's disease had one or more of these manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/1\">",
"     1",
"    </a>",
"    ]. These manifestations were more frequent with colitis than with inflammation limited to the small bowel (42 versus 23 percent).",
"   </p>",
"   <p>",
"    The observation that the extraintestinal symptoms generally improve or disappear when the gastrointestinal disease is effectively treated suggests that the association is causal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ]. The precise mechanisms by which this occurs are not fully understood.",
"   </p>",
"   <p>",
"    The mechanisms by which gastrointestinal disease may induce rheumatic symptoms are reviewed here. The clinical manifestations, diagnosis, and treatment of arthritis associated with gastrointestinal disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult human gastrointestinal tract is not a complete barrier, being permeable to some macromolecules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/8\">",
"     8",
"    </a>",
"    ]. Permeability is increased in certain disease states, including inflammatory bowel disease, celiac disease, and stress [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Environmental factors can also influence gastrointestinal permeability including the administration of nonsteroidal antiinflammatory drugs, excessive chronic alcohol intake, and gastrointestinal pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. Thus, the adult gastrointestinal tract is a potential source for exposure to both bacterial and dietary antigens, particularly when permeability is increased.",
"   </p>",
"   <p>",
"    The epithelial lining of the gastrointestinal tract is one cell thick and includes specialized cells (M cells) that permit transepithelial transport of foreign material from the lumen to mucosal lymphoid tissues. The intraepithelial pocket of the M cell contains many T and B lymphocytes and occasional macrophages. These cells are closely associated with the plasma membrane of the pocket; studies have suggested that, within the M cell pocket, there is interaction of T cells with antigen presenting B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M cells also have basal processes that extend into the local organized mucosal associated lymphoid tissue (O-MALT). This arrangement allows the M cell to serve as a transepithelial conduit for macromolecules and microorganisms. However, some microorganisms (such as Salmonella, Yersinia, Shigella, and Campylobacter) have learned to exploit the M cell transport system, using it as a means to rapidly infect the mucosa and to promote systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigenic exposure via the gastrointestinal tract usually results in tolerance rather than immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Normal individuals appear to be tolerant to their own intestinal flora, but intolerant to that of others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with active IBD lose tolerance to their own bacterial flora, an abnormality that is reversed when the disease comes under control [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/20\">",
"     20",
"    </a>",
"    ]. Whether this loss of tolerance is a cause or a consequence of the IBD is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ARTHRITIS AND GASTROINTESTINAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;These observations suggest that IBD is a good model for the pathologic events that may predispose a host to extraintestinal manifestations of gastrointestinal disease. Active IBD is characterized by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A breach of gastrointestinal wall integrity",
"     </li>",
"     <li>",
"      Increased permeability to macromolecules",
"     </li>",
"     <li>",
"      Increased exposure to microbial and dietary antigens",
"     </li>",
"     <li>",
"      Loss of tolerance to own bacterial flora",
"     </li>",
"     <li>",
"      Host susceptibility to the increased antigenic load",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arthritis is the most common extraintestinal manifestation of IBD, affecting 23 percent of patients in one series of 700 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/1\">",
"     1",
"    </a>",
"    ]. It may present as a peripheral or axial arthritis. Two patterns of peripheral arthritis have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pauciarticular arthritis, normally a large joint arthritis, affecting predominantly lower limbs; flares of arthritis in affected patients usually accompany flares of the bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A less common pattern is a polyarticular arthropathy that frequently involves the small joints and is less often associated with flares of the inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/21\">",
"       21",
"      </a>",
"      ]. This pattern may last months to years. In some predisposed hosts, the arthritis has a predilection for the axial skeleton; in these patients, the arthritis may also progress independently of the bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also data to suggest that patients who present with undifferentiated spondyloarthropathy or ankylosing spondylitis often have subclinical intestinal inflammation that may be responsible for the arthritis and that may progress to IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In one series, 123 patients with spondyloarthropathy (some of whom had ankylosing spondylitis) underwent ileocolonoscopy and were then monitored regularly, with repeat evaluation performed two to nine years later [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Normal gut histology was present in 32 percent, while acute and chronic inflammatory lesions were noted in 23 and 45 percent, respectively. Acute inflammation was primarily seen in patients with postinfectious reactive arthritis. Eleven patients developed IBD; 10 had chronic inflammatory lesions. This finding plus HLA-B27 negativity were risk factors for the development of IBD in patients with spondyloarthropathy. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    improved the arthritic symptoms but did not prevent progression to IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among a subset of 49 patients in this series who underwent one to three repeat ileocolonoscopies, the following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      None of the patients with initially normal gut histology had gut inflammation at the second study.",
"     </li>",
"     <li>",
"      At the second endoscopy, 16 patients were in remission from their arthritic disease; none had intestinal inflammation.",
"     </li>",
"     <li>",
"      Among the 33 patients with persistent arthritic symptoms, 14 had persistent, primarily chronic intestinal inflammation; six of these patients developed IBD.",
"     </li>",
"     <li>",
"      Seven of nineteen patients with undifferentiated spondyloarthropathy progressed to ankylosing spondylitis; all had persistent intestinal inflammation.",
"     </li>",
"     <li>",
"      In 11 patients with more than two ileocolonoscopies, clinical remission of the arthritis was always associated with normal gut histology; furthermore, flares of the joint disease were related temporally to reappearance of gut inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other diseases, such as celiac disease, are also associated with disruption of the intestinal barrier, increased permeability to macromolecules, and the development of extraintestinal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Celiac disease (CD) is an important example of dietary antigens provoking significant pathology, both inside and outside of the gut in a genetically predisposed host. CD is a worldwide disease with a prevalence of 1 percent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/26\">",
"     26",
"    </a>",
"    ]. This figure is much higher than had previously been thought, as prior to 2003, only 1 in 4700 Americans had been diagnosed with celiac disease, showing that at that time approximately 97 percent of American patients were undiagnosed. Many patients with celiac disease do not present with gastrointestinal complaints. This disease is associated with several autoimmune diseases including: diabetes, Addison disease, Sj&ouml;gren&rsquo;s syndrome, and thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/27\">",
"     27",
"    </a>",
"    ]. The prevalence of celiac disease in 151 children with chronic juvenile idiopathic arthritis was found to be 6.7 percent compared with 0.6 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Celiac disease is a genetically controlled disease (95 percent of CD patients carry either the DQ2 or DQ8 HLA genes compared with 30 percent of normals), with a known environmental trigger, gluten. Oral exposure to antigen usually results in tolerance, but in patients with CD it is an immune stimulant resulting in the production of antibody molecules to an enzyme known as tissue transglutaminase (tTg antibodies) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/29\">",
"     29",
"    </a>",
"    ]. Measuring antibodies to tTg is now a recognized screening test for celiac disease. Other studies have shown that the timing of gluten exposure in infants to earlier than three months of age or later than six months of age is a risk factor for the development of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/30\">",
"     30",
"    </a>",
"    ]. Removal of gluten from the diet usually results in a cure of the gastrointestinal complaints of the disease, but other extraintestinal complaints and autoimmune disease may continue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Evidence for bacterial involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an enormous role for the gastrointestinal flora in the metabolism of zenobiotic agents, and maintaining gastrointestinal integrity and good health [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/31\">",
"     31",
"    </a>",
"    ]. Problems similar to those found in CD occur in patients with exposure to bacterial antigen, a consequence of abnormal gastrointestinal flora and bowel bacterial overgrowth. An arthritis-dermatitis syndrome has been described in approximately 25 percent of individuals undergoing a small bowel bypass operation designed to reduce obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Considered to be a consequence of bacterial overgrowth in the residual small bowel blind loop, this syndrome resolved with antibiotic therapy or with reversal of the small bowel bypass.",
"   </p>",
"   <p>",
"    A rat model has been developed which clearly demonstrates that monoarthritis can be reactivated by the induction of experimental small bowel overgrowth induced by the creation of self-filling blind loops [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/34\">",
"     34",
"    </a>",
"    ]. In comparison, the arthritis did not reactivate in control animals that had self-emptying loops and others with sham operations.",
"   </p>",
"   <p>",
"    A study comparing the fecal organisms in patients with early rheumatoid arthritis to those found in patients with fibromyalgia detected significant microbial differences between these two patient groups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/35\">",
"     35",
"    </a>",
"    ]. Similar changes have been reported in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/36\">",
"     36",
"    </a>",
"    ] and alterations of colonic flora have been shown to influence the expression of adjuvant and collagen-induced arthritis in animal models with more severe disease occurring in germ-free animals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some circumstances, a specific causative organism can be identified. As an example, Whipple's disease, which can present with arthritis, carditis, or neurologic complaints long before gastrointestinal symptoms become manifest, is an infectious process caused by a bacillus known as Tropheryma whippelii. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .) Similarly, bowel pathogens such as Salmonella, Yersinia, Shigella, and Campylobacter can invade the bowel wall to produce both local and systemic disease and, in some predisposed individuals, a postinfectious reactive state that may be associated with arthritis, iritis and dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At first glance, the detection in synovium of lipopolysaccharide, and bacterial RNA and DNA suggests that organisms can migrate from the gastrointestinal tract to joints [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the inability to culture bacteria from the synovium of inflamed joints favors the interpretation that nonviable organisms or debris are responsible for the inflammatory response.",
"   </p>",
"   <p>",
"    Trafficking of lymphocytes from Peyer's patches to joints has been reported, with B-cells reactive to bacterial antigens playing a role in producing articular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/40\">",
"     40",
"    </a>",
"    ]. A paradoxical decrease in the T-cell response to antigens of the causative bacteria is associated with active Yersinia infection, possibly slowing bacterial elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chlamydia trachomatis is an important pathogen that can lead to reactive arthritis and localization of Chlamydial DNA, mRNA, and ribosomal RNA within the synovium has led some to suggest that persistent infection by organisms in a dormant phase may contribute to synovitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of spondyloarthritis\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detecting yersinia and salmonella DNA in synovial tissues has proven to be more difficult and it has been suggested that lymph nodes may be the reservoir for these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inflammation of the bowel mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;From 44 to 66 percent of patients with spondyloarthropathy have microscopic inflammatory lesions of the bowel mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. There are two types of lesions: acute, which resembles acute bacterial enterocolitis; and a chronic ileocolitis that is often indistinguishable from Crohn's disease. Furthermore, there are similarities between the immune alterations in spondyloarthropathy and Crohn's disease leading some to suggest that these are distinct clinical phenotypes of a common immune mediated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/44\">",
"     44",
"    </a>",
"    ], possibly being expressed in a genetically different host [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/45\">",
"     45",
"    </a>",
"    ], as the mutations of the",
"    <span class=\"nowrap\">",
"     CARD15/NOD2",
"    </span>",
"    gene that have been associated with Crohn's disease have not been found in ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased expression of alpha-E-beta-7 in T cells from patients with spondyloarthropathy and in the intestinal lymphocytes of patients with Crohn's.",
"     </li>",
"     <li>",
"      Increased expression of epithelial E-cadherin",
"     </li>",
"     <li>",
"      Increased expression of CD163 positive macrophages in Crohn's disease and spondyloarthropathy, but not in ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relative contribution of T helper 1 cells",
"     </li>",
"     <li>",
"      Presence of IgA antibodies to Saccharomyces cerevisiae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These mucosal lesions are not usually associated with bowel symptoms, such as diarrhea, abdominal pain, or urgency that are typically present in idiopathic inflammatory bowel disease. There is a strong relationship between active peripheral arthritis and histological gut inflammation. Approximately 20 percent of patients with IBD present with signs or symptoms of spondyloarthropathy. Medications that interfere with gut inflammation, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , may be effective for the treatment of the peripheral arthritis associated with spondyloarthropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recent work has suggested that interleukin (IL)-23, a proinflammatory cytokine, plays a major role in the development of autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/48\">",
"     48",
"    </a>",
"    ] and the development of experimental colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/49\">",
"     49",
"    </a>",
"    ]. The gene for the IL-23 receptor (IL-23R) has also been identified as an inflammatory bowel gene [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/50\">",
"     50",
"    </a>",
"    ]. IL-23 promotes maturation of autoreactive T cells and consequently stimulates the production of IL-17, another proinflammatory cytokine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recent study designed to evaluate some of the immunological abnormalities in patients with spondyloarthropathies and subclinical inflammatory bowel disease used quantitative gene analysis from intestinal bowel biopsies from patients with Crohn's disease [CD], ankylosing spondylitis [AS], and normal controls [NC] [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/52\">",
"     52",
"    </a>",
"    ]; the study found that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-23p 19 transcripts were upregulated in the terminal ileum of patients with CD and AS.",
"     </li>",
"     <li>",
"      IL-23 was produced by infiltrating monocyte-like cells in the inflamed mucosa from AS and CD biopsies.",
"     </li>",
"     <li>",
"      Paneth cells also are a major source of IL-23 in the terminal ileum in both physiologic and pathologic states. It is important to note that Paneth cells also express NOD-2, and NOD-2 dysregulation plays a role in the pathogenesis of CD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike the patients with CD, overexpression and upregulation of IL-23 was not associated with an upregulation of IL-17 in AS patients with subclinical inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic contributions",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-B27 is associated with axial involvement in inflammatory bowel disease. Genes other than HLA-B27 may contribute to the risk of developing peripheral arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Role of HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients carrying HLA-B27 are predisposed to a characteristic pathology known to consist of an inflammatory enthesopathy that results in bone erosion and that leads to bony ankylosis. Additional features of this spectrum of HLA B27 pathology include inflammation in the eye (iritis and conjunctivitis), arthritis, urethritis, and skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/53\">",
"     53",
"    </a>",
"    ]. This pathology is considered to be a postinfectious reactive pathology, triggered in these susceptible patients by exposure to certain bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transgenic rats carrying human HLA-B27 and beta-2-microglobulin develop many of the clinical features found in human reactive arthritis (formerly Reiter syndrome), with inflammatory bowel disease being the initial disease manifestation in the majority of animals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/55\">",
"     55",
"    </a>",
"    ]. Susceptibility to this disease is related to gene copy number and expression of HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/56\">",
"     56",
"    </a>",
"    ]. However, HLA-B27 is not expressed on gut epithelium, even in chronic inflammatory bowel lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, if the transgenic rats are raised in a germ-free environment, they do not develop the gastrointestinal and joint inflammation but the skin and male genital lesions are unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings demonstrate the need for a specific host predisposing factor and an environmental factor (exposure to bacterial pathogens) to produce disease. Animal studies designed to evaluate the relationship between HLA-B27 and exposure to Gram negative organisms have shown persistence of whole Yersinia organisms at two and four weeks after infection in HLA-B27 positive animals but not controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/59\">",
"     59",
"    </a>",
"    ]. In some, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/60\">",
"     60",
"    </a>",
"    ], studies, the HLA-B27 antigen was found to alter the invasiveness of Gram negative bacteria, an effect that appears to require the ME I epitope of B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/61\">",
"     61",
"    </a>",
"    ]. HLA-B27 also prolongs the intracellular survival of organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/60\">",
"     60",
"    </a>",
"    ]. The presence of infection alters the length and sequence of peptides presented by HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/62\">",
"     62",
"    </a>",
"    ], with such peptides derived from arthritogenic bacteria being able to promote an autoimmune response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, human hosts carrying the B27 antigen may have an impaired ability to process and present certain bacterial antigens to immune cells, a defect that results in the persistence of bacterial antigens at sites distal to the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The persistence of foreign antigen may serve as a constant source of immune stimulation, leading to chronic irreversible pathology. It is these HLA-B27 positive individuals who develop persistent arthritis and spondylitis in the presence of inflammatory bowel disease and in response to an infection of the bowel or urethrogenital tract. The demonstration of bacterial antigens and whole organisms in peripheral joints in these patients, years after the initial infection has blurred the distinction between truly infected and post infectious arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have led to the hypothesis that antibiotics might be beneficial in patients with reactive arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/67\">",
"     67",
"    </a>",
"    ]. However, an animal model of reactive arthritis associated with Yersinia infection demonstrated that only early and adequate antibiotic therapy prevented disease; initiation of therapy after the onset of arthritis was without benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/41\">",
"     41",
"    </a>",
"    ]. Further studies, however, have suggested that a combination of antibiotics may benefit patients with known previous chlamydia infection and a post-reactive arthritic state [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is not persistent mucosal infection, then one must address the ongoing stimulus for a postinfectious disease state that may last for years. It has been suggested that molecular mimicry may be important. According to this hypothesis, an appropriate immune response, initially mounted against a pathogen, is then inappropriately directed at the host. Evidence supporting this hypothesis is provided by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The expression of disease in the transgenic rat model is altered by being raised in a germ free environment [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphocytes (CD8+ T cells) that are both bacteria specific and autoreactive have been demonstrated in patients with ankylosing spondylitis and post infectious arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ankylosing spondylitis eventually develops in 20 percent of postinfectious B27 patients and approximately 50 percent of B27 positive patients with inflammatory bowel diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of observations have suggested a possible role for molecular mimicry against bacterial antigens in ankylosing spondylitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in frequency in HLA-B35, and HLA-DRB1*0103 has been described in those with a type I peripheral arthritis; type II arthropathy has been associated with HLA-B44 (and not B27) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Among patients with ulcerative colitis, the presence of a combination of tumor necrosis factor (TNF) genes (TNFa6b5) and certain HLA-DR types (ie, HLA-DR1, DR7, or DR11) may increase the risk of developing articular symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large-scale screening for single nucleotide polymorphisms (SNPs) in 1000 patients with AS and 1500 controls revealed a significant association of AS with IL-23R [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/76\">",
"     76",
"    </a>",
"    ]. IL-23R is also associated with Crohn's disease and psoriasis, but was also found in patients with only AS. The association of AS with IL-23R was one of the first indications that the TH17 lymphocyte pathway may be involved in the pathogenesis of this disease. This same study also revealed a strong association with the gene ERAP1, previously known as ARTS-1, which has not been found to be associated with either Crohn's disease or psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dietary antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;If exposure to excessive amounts of bacterial antigen can produce disease, a similar response might occur after exposure to excessive amounts of dietary antigens. As an example, some patients with selective IgA deficiency may have excessive absorption of food proteins, develop circulating immune complexes, and progress to develop autoimmune diseases such as rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/77\">",
"     77",
"    </a>",
"    ]. Food-related arthritis has also been demonstrated in some animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to certain bacteria plays a critical role in the development and recrudescence of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. It has also been suggested that altering the dietary habits of a patient predisposed to spondylitis can minimize flares of the disease by altering the bacterial flora secondary to the dietary manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/82\">",
"     82",
"    </a>",
"    ]. Other studies have shown that the use of probiotics can improve histological disease and reduce the secretion of proinflammatory cytokines in animal models with colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/83\">",
"     83",
"    </a>",
"    ] and stabilize the intestinal mucosal barrier in children with atopic dermatitis, a factor that is known to affect the severity of the dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of human and animal studies with probiotics (live organisms) and prebiotics (non-digestible substances that can alter colonic flora) in inflammatory bowel disease models [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6377/abstract/85\">",
"     85",
"    </a>",
"    ], concluded that large, randomized double-blind placebo-controlled clinical trials are need to determine the efficacy and safety of these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4421595\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adult gastrointestinal tract is a potential source for exposure to both bacterial and dietary antigens, particularly when permeability is increased. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Gastrointestinal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of medical conditions, including inflammatory bowel disease (IBD) and celiac disease, may be associated with abnormalities of the gastrointestinal wall, with increased permeability, and with extraintestinal manifestations. As examples, patients with IBD may develop peripheral or axial arthritis, and celiac disease may be associated with a variety of other autoimmune disorders. Patients with spondyloarthritis also often exhibit subclinical intestinal inflammation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Arthritis and gastrointestinal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that may be important in the pathophysiology of rheumatic disease manifestations of gastrointestinal disease include bacterial overgrowth, other alterations in intestinal flora, inflammation of the bowel mucosa, genetic factors affecting the immune response, and dietary antigens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evidence for bacterial involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Inflammation of the bowel mucosa'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Genetic contributions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Dietary antigens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/1\">",
"      Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/2\">",
"      WRIGHT V, WATKINSON G. THE ARTHRITIS OF ULCERATIVE COLITIS. Br Med J 1965; 2:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/3\">",
"      Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med 1989; 72:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/4\">",
"      Gudbj&ouml;rnsson B, H&auml;llgren R. Cutaneous polyarteritis nodosa associated with Crohn's disease. Report and review of the literature. J Rheumatol 1990; 17:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/5\">",
"      Dyer NH, Verbov JL, Dawson AM, et al. Cutaneous polyartheritis nodosa associated with Crohn's disease. Lancet 1970; 1:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/6\">",
"      Meyers S, Dikman S, Spiera H, et al. Cutaneous vasculitis complicating coeliac disease. Gut 1981; 22:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/7\">",
"      Mielants H, Veys EM, Verbraeken H, et al. HLA-B27 positive idiopathic acute anterior uveitis: a unique manifestation of subclinical gut inflammation. J Rheumatol 1990; 17:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/8\">",
"      Walker WA, Isselbacher KJ. Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology 1974; 67:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/9\">",
"      Parke AL, Fagan EA, Chadwick VS, Hughes GR. Coeliac disease and rheumatoid arthritis. Ann Rheum Dis 1984; 43:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/10\">",
"      Smith MD, Gibson RA, Brooks PM. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1985; 12:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/11\">",
"      Kiliaan AJ, Saunders PR, Bijlsma PB, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol 1998; 275:G1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/12\">",
"      Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 2:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/13\">",
"      Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol 1996; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     Neutra MR, Giannasca PJ, Giannasca KT, et al. M cells and microbial pathogens. In: Infections of the GI Tract, Blaser MJ, et al (Eds), Raven Press, New York 1995. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/15\">",
"      Weiner HL. Oral tolerance. Proc Natl Acad Sci U S A 1994; 91:10762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/16\">",
"      Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/17\">",
"      Beck IT, Dinda PK. Acute exposure of small intestine to ethanol: effects on morphology and function. Dig Dis Sci 1981; 26:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/18\">",
"      Wu Z, Nybom P, Magnusson KE. Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1. Cell Microbiol 2000; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/19\">",
"      Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003; 52:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/20\">",
"      Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/21\">",
"      Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/22\">",
"      De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/23\">",
"      Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/24\">",
"      Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/25\">",
"      Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/26\">",
"      Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/27\">",
"      Barton SH, Murray JA. Celiac disease and autoimmunity in the gut and elsewhere. Gastroenterol Clin North Am 2008; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/28\">",
"      Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/29\">",
"      Jabri B, Sollid LM. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/30\">",
"      Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005; 293:2343.",
"     </a>",
"    </li>",
"    <li>",
"     Hill MJ. Role of Gut Bacteria in Human Toxicology and Pharmacology, Taylor and Francis, London 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/32\">",
"      Wands JR, LaMont JT, Mann E, Isselbacher KJ. Arthritis associated with intestinal-bypass procedure for morbid obesity. Complement activation and characterization of circulating cryoproteins. N Engl J Med 1976; 294:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/33\">",
"      Drenick EJ, Ahmed AR, Greenway F, Olerud JE. Cutaneous lesions after intestinal bypass. Ann Intern Med 1980; 93:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/34\">",
"      Lichtman SN, Wang J, Sartor RB, et al. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers. Infect Immun 1995; 63:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/35\">",
"      Vaahtovuo J, Munukka E, Korkeam&auml;ki M, et al. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/36\">",
"      Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/37\">",
"      Breban MA, Moreau MC, Fournier C, et al. Influence of the bacterial flora on collagen-induced arthritis in susceptible and resistant strains of rats. Clin Exp Rheumatol 1993; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/38\">",
"      Hughes RA, Keat AC. Reiter's syndrome and reactive arthritis: a current view. Semin Arthritis Rheum 1994; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/39\">",
"      Wuorela M, Granfors K. Infectious agents as triggers of reactive arthritis. Am J Med Sci 1998; 316:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/40\">",
"      Brandtzaeg P. Review article: Homing of mucosal immune cells--a possible connection between intestinal and articular inflammation. Aliment Pharmacol Ther 1997; 11 Suppl 3:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/41\">",
"      Zhang Y, Gripenberg-Lerche C, S&ouml;derstr&ouml;m KO, et al. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum 1996; 39:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/42\">",
"      Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/43\">",
"      De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002; 4:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/44\">",
"      Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 2005; 7:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/45\">",
"      Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/46\">",
"      van der Paardt M, Crusius JB, de Koning MH, et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/47\">",
"      Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005; 64:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/48\">",
"      Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/49\">",
"      Becker C, Dornhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 2006; 177:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/50\">",
"      Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/51\">",
"      Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/52\">",
"      Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/53\">",
"      Keat A. Why the joint, why the eye? Clin Rheumatol 1996; 15 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/54\">",
"      Uksila J, Toivanen P. HLA-B27 and bacteria. Clin Rheumatol 1996; 15 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/55\">",
"      Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/56\">",
"      Taurog JD, Maika SD, Simmons WA, et al. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993; 150:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/57\">",
"      Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 1993; 178:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/58\">",
"      Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/59\">",
"      Ismail N, Chamberlain J, Inman RD. Persistence and dissemination of Yersinia enterocolitica 0.8 after intra gastric challenge in B27-transgenic mice. Arthritis Rheum 1994; 37:S311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/60\">",
"      Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997; 27:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/61\">",
"      Kapasi K, Inman RD. ME1 epitope of HLA-B27 confers class I-mediated modulation of gram-negative bacterial invasion. J Immunol 1994; 153:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/62\">",
"      Boisg&eacute;rault F, Mounier J, Tieng V, et al. Alteration of HLA-B27 peptide presentation after infection of transfected murine L cells by Shigella flexneri. Infect Immun 1998; 66:4484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/63\">",
"      Maksymowych WP, Ikawa T, Yamaguchi A, et al. Invasion by Salmonella typhimurium induces increased expression of the LMP, MECL, and PA28 proteasome genes and changes in the peptide repertoire of HLA-B27. Infect Immun 1998; 66:4624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/64\">",
"      Bas S, Griffais R, Kvien TK, et al. Amplification of plasmid and chromosome Chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. Arthritis Rheum 1995; 38:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/65\">",
"      Rahman MU, Cheema MA, Schumacher HR, Hudson AP. Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 1992; 35:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/66\">",
"      Merilahti-Palo R, S&ouml;derstr&ouml;m KO, Lahesmaa-Rantala R, et al. Bacterial antigens in synovial biopsy specimens in yersinia triggered reactive arthritis. Ann Rheum Dis 1991; 50:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/67\">",
"      Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992; 35:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/68\">",
"      Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/69\">",
"      Hermann E, Yu DT, Meyer zum B&uuml;schenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993; 342:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/70\">",
"      Fiorillo MT, Maragno M, Butler R, et al. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest 2000; 106:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/71\">",
"      Duchmann R, May E, Ackermann B, et al. HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis. Scand J Immunol 1996; 43:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/72\">",
"      Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/73\">",
"      Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep 2000; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/74\">",
"      Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/75\">",
"      N&uacute;&ntilde;ez C, Alecsandru DM, Mendoza JL, et al. Genetic markers linked to rheumatoid arthritis are also strongly associated with articular manifestations in ulcerative colitis patients. Hum Immunol 2006; 67:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/76\">",
"      Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/77\">",
"      Cunningham-Rundles C, Brandeis WE, Pudifin DJ, et al. Autoimmunity in selective IgA deficiency: relationship to anti-bovine protein antibodies, circulating immune complexes and clinical disease. Clin Exp Immunol 1981; 45:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/78\">",
"      Coombs RR, Oldham G. Early rheumatoid-like joint lesions in rabbits drinking cows' milk. Int Arch Allergy Appl Immunol 1981; 64:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/79\">",
"      Olhagen B, M&aring;nsson I. Intestinal Clostridium perfringens in rheumatoid arthritis and other collagen diseases. Acta Med Scand 1968; 184:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/80\">",
"      Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/81\">",
"      Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/82\">",
"      Ebringer A, Wilson C. The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin Rheumatol 1996; 15 Suppl 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/83\">",
"      Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/84\">",
"      Rosenfeldt V, Benfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004; 145:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6377/abstract/85\">",
"      Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol Clin North Am 2005; 34:465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7789 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6377=[""].join("\n");
var outline_f6_14_6377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4421595\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GASTROINTESTINAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ARTHRITIS AND GASTROINTESTINAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Evidence for bacterial involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inflammation of the bowel mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic contributions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Role of HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dietary antigens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4421595\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6378="Kt/V and the adequacy of hemodialysis";
var content_f6_14_6378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kt/V and the adequacy of hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6378/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/14/6378/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/14/6378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central issue in the management of patients undergoing maintenance hemodialysis is the assessment of adequacy of dialysis. Simply following the blood urea nitrogen (BUN) is insufficient because a low BUN can reflect inadequate nutrition rather than sufficient dialytic urea removal. Monitoring the patient's symptoms alone is also insufficient, since the combination of dialysis plus erythropoietin to correct anemia can eliminate most uremic symptoms although the patient may be underdialyzed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .) Thus, in addition to symptoms, patient nutrition and survival appear to best reflect dialysis adequacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cooperative Dialysis Study (NCDS) established that the timed average urea concentration and the protein catabolic rate (PCR) were important determinants of morbidity and mortality in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .) In particular, well-nourished patients with a more intensive dialysis prescription and a lower timed average BUN had a better outcome. In a patient with little or no urine output, the PCR (in",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    is equal to the sum of the dialysis and stool losses of urea, protein, and amino acids. These losses (the PCR) are roughly equal to protein intake when a patient is in a steady state with a relatively constant predialysis BUN.",
"   </p>",
"   <p>",
"    Gotch later used a mechanistic analysis of these data and showed that the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of urea (see below) was an important measure of clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/3\">",
"     3",
"    </a>",
"    ]. Urea was chosen by the NCDS as the clearance marker for the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    since it is a reflection both of dietary protein intake and of the efficiency of removal of small uremic toxins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individualizing the hemodialysis prescription to a particular patient's needs using",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    can be a useful tool in providing a safe and cost-effective dialysis treatment. This can be accomplished with",
"    <strong>",
"     urea kinetic modeling",
"    </strong>",
"    , which allows for variations in dialysis time, use of larger, high efficiency, high-flux dialyzers, and optimization of dietary protein need. Urea kinetic modeling is a method for verifying that the amount of dialysis prescribed (the prescribed",
"    <span class=\"nowrap\">",
"     Kt/V)",
"    </span>",
"    equals the amount of dialysis delivered (the effective",
"    <span class=\"nowrap\">",
"     Kt/V).",
"    </span>",
"    Kinetic modeling also quantifies the amount of urea generated, which is a marker of the protein catabolic rate and therefore of protein",
"    <span class=\"nowrap\">",
"     intake.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION AND CALCULATION OF KT/V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kt/V",
"    is defined as the dialyzer clearance of urea (",
"    <strong>",
"     K",
"    </strong>",
"    , obtained from the manufacturer in",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and periodically measured and verified by the dialysis team) multiplied by the duration of the dialysis treatment (",
"    <strong>",
"     t",
"    </strong>",
"    , in minutes) divided by the volume of distribution of urea in the body (",
"    <strong>",
"     V",
"    </strong>",
"    , in mL), which is approximately equal to the total body water. The correction of total urea removal (Kt) for volume of distribution is important because, in a large patient, a given degree of urea loss represents a lower rate of removal of the total body burden of urea (and presumably of other small uremic toxins).",
"   </p>",
"   <p>",
"    As stated in the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, the preferred method for measurement of the dialysis dose is by formal kinetic urea modeling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/4\">",
"     4",
"    </a>",
"    ]. The optimal value for",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    will be discussed below after reviewing the different methods that can be used to calculate this parameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Computer models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perception that calculation of the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    requires the use of advanced mathematics had retarded its acceptance and use. However, computer software packages can be purchased separately or as an integral component of the dialysis machine.",
"   </p>",
"   <p>",
"    When supplied with simple clinical information (predialysis and postdialysis weights, ultrafiltration volume, hematocrit, and predialysis and postdialysis BUN), computer programs will perform the necessary computations and print the",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    PCR, and other data in a readable format that can be used to alter the dialysis prescription if necessary. Furthermore, current hemodialysis machines have built-in computers that gather and store clinical data during dialysis (blood pressure, blood flow rate, dialysis flow rate, nursing entries of body weight, etc). These data becomes the basis of the urea modeling program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Statistical models",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a computer modeling program is not available, a simple approach that achieves nearly the same results can be obtained with a hand held calculator and a few simple equations. The central and most important measurement for these models is the ratio of the postdialysis to predialysis BUN; more complex models add the refinements of accounting for urea generated during the dialysis procedure and for dialysis-induced changes in total body water. Both urea generation and fluid removal during dialysis increase the postdialysis BUN. As a result, models that ignore urea generation and volume changes yield a lower value for",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    since it appears that dialysis has been less efficient.",
"   </p>",
"   <p>",
"    In addition to urea generation and dialysis-induced changes in body water, the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is affected by the equilibration of urea from skeletal muscle to plasma water. As will be discussed below, urea-rich blood in the venous circulation is not actually measured with the postdialysis BUN sample. Instead, this sample consists of arterial blood flowing into the extracorporeal circuit under conditions in which vascular access recirculation is minimized. The",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    calculated from this sample is called the single pool, nonequilibrated",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"   </p>",
"   <p>",
"    By comparison, a postdialysis urea sample that reflects the equilibration of muscle and blood urea is called an equilibrated sample, representing the blood and muscle cell pool of urea within the body (eg, the double pool of urea). Given that the urea concentration measured with the equilibrated sample is higher than that observed in the nonequilibrated sample, the equilibrated, double pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is lower than the nonequilibrated, single pool",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    This difference is approximately 0.21 for the usual range of delivered doses of hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/5\">",
"     5",
"    </a>",
"    ], and decreases with longer hemodialysis treatment times (t).",
"   </p>",
"   <p>",
"    Continuous peritoneal dialysis is an equilibrated condition; however, most studies of hemodialysis patients utilize single pool, nonequilibrated",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    Unless otherwise stated, the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    referred to herein is the single-pool, nonequilibrated value.",
"   </p>",
"   <p>",
"    The following formula and accompanying nomogram has little systematic error for",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values between 0.7 and 2.0, a range that covers the currently recommended",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    goals (",
"    <a class=\"graphic graphic_figure graphicRef64426 \" href=\"UTD.htm?21/32/22030\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp;",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &nbsp; = &nbsp; -ln (R &nbsp;- &nbsp;0.03) &nbsp;+ &nbsp;[(4 &nbsp;- &nbsp;3.5R) &nbsp;x &nbsp;(UF &nbsp;&divide; &nbsp;W)]",
"   </p>",
"   <p>",
"    where UF is the ultrafiltration volume in liters, W is the postdialysis weight in kg, and R is the ratio of the postdialysis to predialysis BUN. This formula also appears to be valid in children, including those less than 30 kg in weight [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/8\">",
"     8",
"    </a>",
"    ]. A calculator capable of performing natural logarithms is required to determine the",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"   </p>",
"   <p>",
"    The formula for the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    in the following calculator also takes the length of the dialysis session into consideration (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/58/35745?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urea reduction ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simpler model uses the urea reduction ratio (URR):",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; URR &nbsp; = &nbsp; (1 &nbsp;- &nbsp;[postdialysis BUN &nbsp;&divide; &nbsp;predialysis BUN])",
"   </p>",
"   <p>",
"    Thus, the URR is 0.6 if the postdialysis BUN is 40 percent that of the predialysis value. Other investigators have used the percent reduction in urea (PRU), which involves the same calculation as the URR except that the result is multiplied by 100 to be expressed as a percentage.",
"   </p>",
"   <p>",
"    Several different equations have been proposed to estimate the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    from the PRU [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &nbsp; = &nbsp; (0.026 &nbsp;x &nbsp;PRU) &nbsp;- &nbsp;0.460",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &nbsp; = &nbsp; (0.024 &nbsp;x &nbsp;PRU) &nbsp;- &nbsp;0.276",
"   </p>",
"   <p>",
"    As an example, a postdialysis BUN that is 40 percent of the predialysis value corresponds to a PRU of 60 percent and a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.10 and 1.16, respectively.",
"   </p>",
"   <p>",
"    Because of its ease of calculation, the URR is frequently utilized in epidemiologic studies. One study evaluated the correlation between various demographic characteristics and a URR of less than 65 percent, a hemodialysis dose that is less than the currently recommended minimum amount [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/11\">",
"     11",
"    </a>",
"    ]. Among all variables analyzed, heavy patients (as defined by body weight in the heaviest quartile) were those most likely to receive inadequate dialysis (odds ratio of 6.1).",
"   </p>",
"   <p>",
"    These equations, although reasonably accurate, are not a substitute for the more complete formula noted above in Equation 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Although the URR is useful as an epidemiologic tool, its efficacy in individual patients is more limited because of a relatively broad range of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    that may be seen at a given URR. One study found that a median URR of 0.62 was associated with a median",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.12 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/13\">",
"     13",
"    </a>",
"    ]. However,",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values below 1.0 (indicating underdialysis) and above 1.30 (indicating adequate dialysis) were each seen in 10 percent of cases with this URR.",
"   </p>",
"   <p>",
"    This variability is due in part to urea removal with ultrafiltration, which is not considered in the URR. A large ultrafiltration requirement alone can raise the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    by 0.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/13\">",
"     13",
"    </a>",
"    ]. Formulas have been published that attempt to correct for this and other effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, as previously mentioned, there are other advantages to using formula kinetic modeling and not the URR. Measuring the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    provides guidance concerning which elements of the prescription require modification to achieve the target dialysis dose. As an example, technical problems with the hemodialysis session should be considered when the V derived from formal modeling differs from the V obtained via other equations; such information is not available if the clinician relies upon the URR alone.",
"   </p>",
"   <p>",
"    These and other similarly derived equations correlate reasonably well with the more rigorous urea kinetic modeling when the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and PCR are in the normal or expected range [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/6\">",
"     6",
"    </a>",
"    ]. They are most accurate when the true",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is between 0.7 and 1.3 (URR of approximately 40 to 65 percent), the dialysis time is three to five hours, and total body water is 50 to 60 percent of body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postdialysis BUN",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue is the",
"    <strong>",
"     time",
"    </strong>",
"    at which the postdialysis BUN should be measured. Within two minutes after dialysis, both access and cardiopulmonary recirculation have dissipated, and the differences in arterial and venous urea concentrations have largely resolved. Many studies have recommended that the postdialysis sample be measured between one and five minutes after dialysis",
"    <strong>",
"     or",
"    </strong>",
"    during slow down (but before the lines have been flushed with saline that can acutely lower the BUN by dilution) (",
"    <a class=\"graphic graphic_figure graphicRef57290 \" href=\"UTD.htm?25/7/25725\">",
"     figure 2",
"    </a>",
"    ). The stop dialysate flow method also appears to be valid in patients receiving hemodiafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=see_link\">",
"     \"Arteriovenous fistula recirculation in hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, with two to four hours of high-flux dialysis, the more rapid reduction in BUN overestimates the true rate of urea removal because there has not been time for sufficient intracellular urea to diffuse out of the cells and equilibrate with extracellular stores [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. Thus, the calculated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    in this setting may exceed the true value by approximately 0.2. Measuring the BUN on a specimen obtained 30 minutes after dialysis is completed can partially correct for this problem, as the value will be higher than that obtained immediately after dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/7,17,19\">",
"     7,17,19",
"    </a>",
"    ]. A similar problem can occur with standard dialysis in patients with delayed urea equilibration with tissue stores (",
"    <a class=\"graphic graphic_figure graphicRef57290 \" href=\"UTD.htm?25/7/25725\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=see_link&amp;anchor=H7#H7\">",
"     \"Prescribed versus delivered dialysis: Importance of dialysis time\", section on 'Diminished urea clearance due to diminished equilibration with intracellular stores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, the equilibrated postdialysis BUN value (eg, the BUN concentration in a specimen obtained 30 minutes after dialysis) is the most accurate measurement. Its use in kinetic modeling avoids an overestimation of the actual hemodialysis dose.",
"   </p>",
"   <p>",
"    However, the equilibrated value is too difficult to perform in the clinical setting. Based upon samples from 70 hemodialysis patients, an attempt was made to identify a formula that correlated the 30 minute postdialysis sample with the five minute postdialysis urea sample obtained using the stop dialysate flow method [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/20\">",
"     20",
"    </a>",
"    ]. A linear regression equation that was prospectively validated using data from 35 dialysis patients was extremely accurate. This equation also appears to be valid in patients receiving hemodiafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incorrect sampling of postdialysis BUN is common and may result in erroneous conclusions concerning the correlation between patient outcomes and the presumed delivery of a specific amount of dialysis. As an example, as part of a study examining the delivery of dialysis in the ESRD Network 1 geographic area in the United States, very little consistency and a large degree of improper blood sampling was observed in a sample of participating dialysis units [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      33 percent of hemodialysis units drew the postdialysis BUN immediately before the end of the session.",
"     </li>",
"     <li>",
"      25 percent drew the sample immediately after the session.",
"     </li>",
"     <li>",
"      42 percent drew the sample more than five minutes after the reinfusion of blood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, any conclusions resulting from these measurements must be suspect. Whether these results accurately reflect the measurement of postdialysis blood samples in other geographic areas is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given these issues, our practice is to slow the blood pump to 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and then obtain the blood sample BUN",
"    <strong>",
"     15 seconds",
"    </strong>",
"    later. This procedure is consistent with the 2006 National Kidney Foundation Dialysis Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    and the European and Canadian hemodialysis guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/4,22,23\">",
"     4,22,23",
"    </a>",
"    ]. Compared to later sampling times, this earlier measurement is thought to be the most accurate method to support formal kinetic modeling. To ensure consistent values, measurement of the postdialysis BUN should be performed exactly the same way each time it is assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OPTIMAL KT/V",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted target value for the",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    Using urea kinetic modeling, a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.05 was initially thought to represent adequate dialysis. It is likely, however, that 1.05 defines only the lower limit of a minimally acceptable dialysis prescription. One study, for example, demonstrating decreased patient survival at urea reduction ratios below 60 percent",
"    <span class=\"nowrap\">",
"     (Kt/V",
"    </span>",
"    less than 1.2) is compatible with the need for more intensive dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many patients were previously underdialyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/25\">",
"     25",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values of 1.3 to 1.6 are now the norm in the United States along with increased use of high-flux dialyzers and concern about the problems with short dialysis session duration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. In the 2007 annual report, the mean delivered single pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of adult in-center dialysis patients in the United States was approximately above 1.5 and over 90 percent of patients had",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values over 1.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. By comparison, a 2004 survey of dialysis practices in the years 1998 to 2000 in five European countries found that the mean delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    varied from 1.28 to 1.50 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate dialysis, however, may be less common among children, although such a dose is not well defined. This was shown in a study of 147 children being dialyzed in 32 centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/33\">",
"     33",
"    </a>",
"    ]. Approximately 30 percent were not being adequately dialyzed, as defined in this study by at least 75 percent of calculated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    measures being &gt;1.2 for a given subject. An inadequate dose was more likely among males, blacks, and those with larger body surface areas. Dialysis using a central venous access is also associated with decreased doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, such decreased doses may be associated with increased comorbidity. A single pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    value of &lt;1.2 in a large cohort of adolescent (12 to 18 years) hemodialysis patients was associated with increased hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/35\">",
"     35",
"    </a>",
"    ]. However, a value of greater than 1.4 afforded no additional benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HEMO study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to address the question of optimal dialysis dose, a large clinical trial, called the Hemodialysis (HEMO) Study, was performed in which 1846 patients were randomly assigned to a standard or high dose of dialysis",
"    <strong>",
"     and",
"    </strong>",
"    a low- or high-flux dialyzer (based on clearance of beta-2-microglobulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/36\">",
"     36",
"    </a>",
"    ]. The standard dose goal was an equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.05, which is equivalent to a urea reduction ratio of 65 percent or a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.25. The high dose goal was an equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.45, which is the same as a urea reduction ratio of 75 percent or a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.65. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access), and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of greater than 15 percent of the serum albumin concentration from baseline value, or death.",
"   </p>",
"   <p>",
"    The following results were reported at a mean follow-up time of 2.8 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impressive separation was obtained for all randomized groups. The standard dose group received an equilibrated",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.16, a single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.32, and a urea reduction ratio of 66.3 percent. The high dose group had values of 1.53, 1.71, and 75.2 percent, respectively. The low and high flux groups had clearances of beta-2-microglobulin of 3 and 34",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The risk of death from any cause, the primary outcome, was the",
"      <strong>",
"       same",
"      </strong>",
"      in the high and standard dose groups (RR of 0.96 for high versus standard dose, CI of 0.84 to 1.10) (",
"      <a class=\"graphic graphic_figure graphicRef81812 \" href=\"UTD.htm?38/27/39357\">",
"       figure 3",
"      </a>",
"      ) and in the high and low flux groups (RR of 0.92) (",
"      <a class=\"graphic graphic_figure graphicRef71570 \" href=\"UTD.htm?35/58/36781\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The risk of the main secondary outcomes was also the",
"      <strong>",
"       same",
"      </strong>",
"      for both dialysis doses and both flux groups. In the high flux group, there were significant reductions, compared with the low flux group, in the risk of death from cardiac causes and the combined outcome of first hospitalizations or death from a cardiac cause. However, as previously mentioned, total mortality was the same in both flux groups.",
"     </li>",
"     <li>",
"      Subgroup analysis revealed a survival benefit for patients with more than 3.7 years of dialysis receiving high flux dialysis (32 percent lower risk than the low flux group). The strength of this interaction between flux and years of dialysis was weakened when years of dialysis was treated as a continuous variable.",
"     </li>",
"     <li>",
"      A significant survival benefit for women receiving a high dialysis dose was observed upon subgroup analysis (19 percent lower risk of death than women in the standard dose group). This benefit remained after adjustment for body volume, body mass index, weight, age, and race [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/37\">",
"       37",
"      </a>",
"      ]. By comparison, men receiving a high dose dialysis had a 16 percent higher risk of death than those receiving standard dose dialysis. The degree to which this reflects a true gender effect is not clear, although some additional observational evidence independently supports the existence of gender differences in survival benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further analysis has found that differences in dialysis dose and membrane also had no effect upon the incidence of infection-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/39\">",
"     39",
"    </a>",
"    ], although the higher dialysis dose has a small but significant benefit in terms of better physical performance and pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/40\">",
"     40",
"    </a>",
"    ]. Subgroup analysis also found that increased serum levels of beta 2 microglobulin correlated with mortality, particularly death due to infectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The clinical significance of this last finding is unclear, although it suggests that increased removal of beta 2 microglobulin with high flux membranes may provide benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns with the HEMO study include the relative exclusion of larger sized patients, disproportionate representation of African-Americans, and enrollment of prevalent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/44\">",
"     44",
"    </a>",
"    ]. However, these concerns are largely unfounded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/45\">",
"     45",
"    </a>",
"    ]. As an example, given that larger sized patients have a lower mortality, the relatively increased number of smaller size patients increased the power of the HEMO study. In addition, the finding of a high degree of correlation between mortality and dialysis dose in the as-treated analysis is unlikely to represent an effect of dose on mortality but rather a bias underlying the effect of mortality on the achieved",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, similar outcomes were observed in the HEMO study with high and standard dialysis doses as well as dialysis using high and low flux membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Residual renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued urine output facilitates the regulation of fluid and electrolyte balance, and may enhance survival. Among peritoneal dialysis patients, the beneficial effect of continued urine output on survival is clear, as shown in multiple studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emerging observational evidence suggests that a survival benefit due to preserved renal function may also occur among hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 650 incident hemodialysis patients, continued residual renal function was correlated with survival and other outcomes over a 15 year period [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/49\">",
"       49",
"      </a>",
"      ]. Among those with continued native renal urea clearance &ge;1",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      mortality was significantly lower at 6, 12, and 24 months after dialysis was initiated versus those without residual function; this benefit was maintained after correcting for albumin, age, comorbidities, hemodiafiltration, and underlying renal disease. Significantly lower",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      values were observed in those with continued residual renal function, suggesting that clearance via native kidneys provides superior benefits to that observed with conventional hemodialysis.",
"     </li>",
"     <li>",
"      The Netherlands Cooperative Study on the Adequacy of Dialysis evaluated the relationship between residual renal function and survival among 740 hemodialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/48\">",
"       48",
"      </a>",
"      ]. At three months after dialysis initiation, the mean",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of urea with residual renal function was 0.6 per week. Survival was directly related to preserved renal function, as each increase of",
"      <span class=\"nowrap\">",
"       1/week",
"      </span>",
"      in the",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      was significantly associated with a lower relative risk of death (0.44). In addition, survival in association with dialysis clearance was dependent upon preserved renal function, with dialysis clearances of less than",
"      <span class=\"nowrap\">",
"       2.9/week",
"      </span>",
"      being associated with a higher mortality only among anuric patients. This value is less than that currently recommended.",
"     </li>",
"     <li>",
"      Among 734 incident hemodialysis patients, the presence of urine output at one year after dialysis initiation, compared to those without residual function, was significantly associated with a lower all cause mortality (HR, 0.70, 95% CI 0.52-0.93) and a trend to decreased cardiovascular mortality (HR, 0.69, 95% CI 0.45-1.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/50\">",
"       50",
"      </a>",
"      ]. Further study is required to understand the effect of continued renal function on survival among hemodialysis patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines suggest that the minimally adequate dose of dialysis can be reduced among patients with residual kidney function of greater than 2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/4\">",
"     4",
"    </a>",
"    ]. Given the absence of data concerning dosing in this setting, they suggest that the minimum single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    can be no lower than 60 percent of the minimum target for those without residual renal function. This is based upon achieving a minimum standard",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 2.0 per week, which is equivalent to dialyzing three times per week to a single pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of approximately 1.2 per 3.5 hours per session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Target value",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognizant of the results from the HEMO study, we continue to aim for a target single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of approximately 1.4 to 1.6 in our unit. We also use a high-efficiency dialyzer and provide dialysis at least three times per week for a period averaging four and one-half hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/51\">",
"     51",
"    </a>",
"    ]. Furthermore, we use an initial blood flow rate of 400",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a dialysate flow rate of 800",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    It",
"    is particularly important that these target dialysis doses are achieved in women or those with high comorbidity, as these subgroups may benefit from higher dialysis doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/37,38,51\">",
"     37,38,51",
"    </a>",
"    ]. Given that the prescribed and delivered dialysis dose can be discordant, this prescription will ensure that the dialysis dose in most patients will be at least a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.32 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/23,45,52\">",
"     23,45,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These levels are consistent with the following 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for hemodialysis patients with minimal residual renal function (less than 2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimally adequate dose should be a single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.2 (or a urea reduction rate of 65 percent)",
"     </li>",
"     <li>",
"      Target recommended dose should be a single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.4 (or a urea reduction rate of 70 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FREQUENCY OF MEASUREMENT OF DIALYSIS DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of the dialysis dose in stable hemodialysis patients is performed once per month by most clinicians. However, some data suggests that the calculated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    in a particular patient may vary quite widely, possibly requiring more frequent measurements",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    average",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values to accurately assess or adjust the dialysis dose. In one study of 50 stable hemodialysis patients, the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    had to be measured at least three times to obtain a reliable and consistent value because of variations in the value of the urea concentration, ultrafiltration volume, and urea clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CORRECTION OF LOW KT/V VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is how to correct a low",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR. The optimal approach is aided by a knowledge of the frequency with which various limiting factors contribute to the low",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    These issues were addressed in a study of 146 stable dialysis patients in whom measurements of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and access recirculation were obtained every month for three successive months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/54\">",
"     54",
"    </a>",
"    ]. An abnormal",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    value was defined as a decline of &ge;0.2 or &ge;0.1 if the baseline",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was &ge;1.2 or &lt;1.2, respectively. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 percent of low",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      values were due to a lower than prescribed blood flow or time of dialysis, which resulted largely from inadequate needle placement and patient initiated time constraints, respectively.",
"     </li>",
"     <li>",
"      25 percent of abnormal values resulted from significant access recirculation.",
"     </li>",
"     <li>",
"      A cause was not uncovered in the remaining patients; however, subsequent",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      values rapidly returned to baseline values without any intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased body mass, impaired sodium removal, and less than optimal dialysate flow rate, blood tubing effects, and needle gauge size may also be unrecognized causes of inadequate hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/55-60\">",
"     55-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quality of hemodialysis delivery was significantly improved in a community-based randomized trial in which regular advice was given to nephrologists responsible for the care of patients identified as receiving inadequate dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/61\">",
"     61",
"    </a>",
"    ]. Specifically, a study coordinator provided patient-specific recommendations every month to help remedy the delivery of a low",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    At six months, optimizing the dialysis prescription, expediting the conversion of catheters to",
"    <span class=\"nowrap\">",
"     grafts/fistulas,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emphasizing the importance of time on dialysis resulted in a two-fold larger increase in",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    compared with patients who received usual care (0.2 and 0.1).",
"   </p>",
"   <p>",
"    Measures aimed at improving the quality of nephrology practice (Quality in Nephrology [QiN]), including increasing the dose of hemodialysis, have also been implemented in some dialysis centers in Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/62\">",
"     62",
"    </a>",
"    ]. Using this QiN system from 1999 to 2003, the dose of dialysis markedly improved over this time period as measured by dialysis duration per session (4.2 versus 4.4 hours),",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    (1.3 versus 1.5), and URR (65 versus 70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/63\">",
"     63",
"    </a>",
"    ]. Measures implemented with this voluntary system included quarterly updates (which compared outcomes in different individual dialysis units) and continuous quality improvement cycles (which used constantly recorded patient data).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithm to help assess the causes of a low",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR was published in the 2000",
"    <span class=\"nowrap\">",
"     K/Dialysis",
"    </span>",
"    Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    clinical practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/64\">",
"     64",
"    </a>",
"    ]. Suggested initial steps include an assessment of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fistula integrity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=see_link\">",
"       \"Arteriovenous fistula recirculation in hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment duration. Common errors associated with dialysis time that is less than prescribed include a late arriving patient, the late initiation of dialysis by staff, early termination because of patient request or clinical events, blood leak, needle difficulties, and excessive triggering of machine alarms.",
"     </li>",
"     <li>",
"      Methods of obtaining BUN samples. Technical errors resulting in an incorrectly low predialysis BUN or a high postdialysis BUN may result in a decreased",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"     </li>",
"     <li>",
"      Dialysis machine and patient specific variables associated with a low",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"      These include inadequate machine calibration, low blood flow rates, episodes of hypotension requiring changes in treatment, overestimation of dialyzer clearance, and others.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A secondary assessment should be performed if the initial analysis does not lead to the quick identification of the cause of or correction of a low",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    This may involve the incorporation of additional measures to improve effective hemodialysis treatment times, correct errors in blood sampling, or improve dialyzer clearance. Attempts to improve clearance may include an assessment of extracorporeal pressures, kinetic modeling of other patients using the same dialyzer model and",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    prescription, measures to decrease dialyzer clotting and fistula recirculation, and calibration of blood and dialysis flows. The use of two dialyzers in series or parallel may be another method to significantly improve clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the primary problem is cardiopulmonary recirculation or delayed transfer of urea out of the cells, then urea clearance of the blood delivered to the dialyzer is already at near maximal levels. As a result, increasing dialyzer size, blood flow, or dialysate flow will produce only a marginal improvement. The only way to compensate for the reduced efficiency of urea removal is to increase the time on dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=see_link\">",
"     \"Prescribed versus delivered dialysis: Importance of dialysis time\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A generally similar approach has been suggested by other international societies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO KT/V FOR ASSESSING ADEQUACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all investigators accept the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    as the optimal method for assessing the adequacy of hemodialysis. Support for this view is provided by the finding that increasing the frequency of dialysis, independent of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    delivered, may result in significant clinical benefits. One study evaluated the clinical consequences of changing from a three times per week dialysis schedule to a daily schedule among 13 chronic home hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/68\">",
"     68",
"    </a>",
"    ]. The weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was approximately 3.2 before and after the change. After six months, improvements were observed in blood pressure control, uremic symptoms, and quality of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other modalities to assess hemodialysis adequacy have therefore been evaluated, although not as extensively as",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    These include the timed average urea concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/27,68\">",
"     27,68",
"    </a>",
"    ], the solute removal index, and the Kt that is not normalized by body volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Solute removal index",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the solute removal index technique, the total amount of urea removed during dialysis is directly measured by multiplying the urea concentration in the dialysate by the volume of spent dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/69\">",
"     69",
"    </a>",
"    ]. Since the solute removal index does not rely upon changes in the concentration of urea in blood, it is unaffected by those factors that significantly alter the",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    such as the timing of the post-dialysis blood sample. As a result, some investigators feel that this method is preferred to blood-based measurements of dialysis adequacy.",
"   </p>",
"   <p>",
"    However, the solute removal index has limitations. These include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of studies correlating patient outcome with the values obtained with this index.",
"     </li>",
"     <li>",
"      The impracticality of collecting the total spent dialysate. However, one study suggested that calculating dialysis removal via a simple partial collection of spent dialysate closely correlated with the calculation obtained from a total collection (r = 0.95, P&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/70\">",
"       70",
"      </a>",
"      ]. In addition, another trial of 52 dialysis treatments in 19 patients found comparable results between blood-based",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      measurements and a dialysate-based",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      estimation that relies upon a commercially available on-line urea sensor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relative inaccuracy of the calculated hemodialysis dose obtained using solute removal indices. In the pilot phase of the HEMO study, the solute removal index and blood-side methods were measured and utilized to calculate the hemodialysis dose in 39 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/71\">",
"       71",
"      </a>",
"      ]. Compared with blood-side methods, larger errors were observed in the calculated equilibrated",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      when the solute index was utilized. With a prescribed",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.4, for example, an error in the collection of dialysate of 7 percent resulted in a 20 percent error in the calculated equilibrated",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-normalized dialysis dose (Kt)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the correction of total urea removal (Kt) for the volume of distribution (V) to result in the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is considered important because a given degree of urea loss represents a lower rate of removal of the total body burden of urea in a larger patient as compared to a smaller individual. However, this formula is a mathematical construct that assumes that V does not alter patient outcome independent of its effect upon the clearance of urea.",
"   </p>",
"   <p>",
"    This is an important issue since there is a body of evidence suggesting that this assumption is not true [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/73-81\">",
"     73-81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Black dialysis patients, despite having a lower URR, have superior survival compared with white patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/73\">",
"       73",
"      </a>",
"      ]. However, mortality in both patient populations correlates with the serum creatinine concentration, an indirect measure of body mass.",
"     </li>",
"     <li>",
"      If body size is unrelated to outcome, then smaller patients with a low volume of urea distribution would require proportionately less total treatment (Kt) than larger patients; if this were correct, a decreased dialysis dose should not adversely affect overall survival among small individuals since",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      would remain at an \"adequate level.\" However, sophisticated mathematical analysis of data relating to body size, dialysis dose, and mortality among over 40,000 patients found that smaller patients had increases in mortality risk with lower dialysis doses [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an increased relative risk of death among patients with extremely high values for",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      (greater than 1.6) or the urea reduction ratio (URR between 75 and 79 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/74,75,79\">",
"       74,75,79",
"      </a>",
"      ]. Support for the hypothesis that the increased death rate may be due to the effects of marked malnutrition comes from a study which evaluated the correlation between mortality, dialysis dose, and body volume in over 3000 dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/75\">",
"       75",
"      </a>",
"      ]. Consistent with previous studies, patients with a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      or URR value in the highest (or fifth) quintile had an increased relative risk of death (19 percent greater than those in the third quintile). However, a higher Kt alone was not associated with an increased relative risk of death, as there was a two percent decrease in mortality risk per liter increase in clearance. Similar results were observed in another much larger study of over 37,000 dialysis patients that examined the relationship between survival and dialysis dose as measured by either the URR or Kt [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/79\">",
"       79",
"      </a>",
"      ]. These observations, in combination with the finding in the first study that patients in the fifth quintile suffered from more severe protein-calorie malnutrition, suggest that the increased mortality associated with very high",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      or URR values reflects poor nutrition.",
"     </li>",
"     <li>",
"      As measured using direct-on line technology, increasing values for small molecular clearance alone are directly and independently associated with a decreasing risk of death [",
"      <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is required to determine whether the Kt alone is a superior measure of the dialysis dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other variables related to dialysis adequacy that correlate with a reduced death risk include dialysis time greater than four hours, predialysis BUN between 70 and 90",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (25 to 32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with an adequate PCR, low requirement for erythropoietin and antihypertensive drugs, and signs of better nutrition such as plasma albumin concentration greater than 4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    plasma cholesterol concentration between 200 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2 to 7.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and predialysis plasma creatinine concentration above 12.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1100",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/24,82-84\">",
"     24,82-84",
"    </a>",
"    ]. As previously mentioned, the improved outcome associated with higher plasma creatinine concentrations is probably a reflection of greater muscle mass in patients who are well nourished. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another method to measure dialysis adequacy involves online conductivity measurement, which does not require frequent sampling of patient blood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. The strategy, which relies upon dialysate inlet and outlet monitors, is based on the observation that changes in dialysate conductivity are comparable with the clearance of urea. However, the conductivity clearance is frequently markedly higher than the urea clearance, although there is some evidence that the error can be overcome with specific conductivity profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?6/14/6378/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8619753\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      is a method for determining the adequacy of dialysis. The",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      is defined as the dialyzer clearance of urea (",
"      <strong>",
"       K",
"      </strong>",
"      , obtained from the manufacturer in",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and periodically measured and verified by the dialysis team) multiplied by the duration of the dialysis treatment (",
"      <strong>",
"       t",
"      </strong>",
"      , in minutes) divided by the volume of distribution of urea in the body (",
"      <strong>",
"       V",
"      </strong>",
"      , in mL), which is approximately equal to the total body water. The correction of total urea removal (Kt) for volume of distribution is important because, in a large patient, a given degree of urea loss represents a lower rate of removal of the total body burden of urea (and presumably of other small uremic toxins). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition and calculation of Kt/V'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A simpler model to determine dialysis adequacy uses the urea reduction ratio (URR). The URR is frequently utilized in epidemiologic studies, however, its efficacy in individual patients is more limited because of a relatively broad range of",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      that may be seen at a given URR. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Urea reduction ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no universally accepted target value for the",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"      We aim for a target single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of approximately 1.4 to 1.6. These levels are consistent with the 2006",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines for hemodialysis patients with minimal residual renal function (less than 2",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Target value'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Residual renal function facilitates the regulation of fluid and electrolyte balance, and may enhance survival. The 2006",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      clinical practice guidelines suggest that the minimally adequate dose of dialysis can be reduced among patients with residual kidney function of greater than 2",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , although the minimum single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      can be no lower than 60 percent of the minimum target for those without residual renal function. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Residual renal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An assessment of the dialysis dose in stable hemodialysis patients is performed once per month by most clinicians, although more frequent measurements may more accurately assess or adjust the dialysis dose. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Frequency of measurement of dialysis dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The search for causes of a low",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      or URR includes an assessment of fistula integrity, treatment duration, possible technical errors in the method of obtaining BUN samples, and dialysis machine- and patient- specific variables such as inadequate machine calibration, low blood flow rates, hypotensive episodes that require changes in treatment, and overestimation of dialyzer clearance. Measures should be incorporated to improve effective hemodialysis treatment times, correct errors in blood sampling, or improve dialyzer clearance. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Algorithm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other modalities to assess hemodialysis adequacy that have been evaluated include the timed average urea concentration, the solute removal index, and the Kt that is not normalized by body volume. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Alternatives to Kt/V for assessing adequacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/1\">",
"      Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/2\">",
"      Harter HR. Review of significant findings from the National Cooperative Dialysis Study and recommendations. Kidney Int Suppl 1983; :S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/3\">",
"      Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/4\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/5\">",
"      Eknoyan, G, Levey, AS, Beck, GJ, et al. The hemodialysis (HEMO) study: rationale for selection of interventions. Semin Dial 1996; 9:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/6\">",
"      Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/7\">",
"      Daugirdas JT, Depner TA. A nomogram approach to hemodialysis urea modeling. Am J Kidney Dis 1994; 23:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/8\">",
"      Goldstein SL, Sorof JM, Brewer ED. Natural logarithmic estimates of Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 1999; 33:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/9\">",
"      Daugirdas JT. Rapid methods of estimating Kt/V: three formulas compared. ASAIO Trans 1990; 36:M362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/10\">",
"      Lowrie, EG, Lew, NL. The urea reduction ratio (URR). A simple method for evaluating hemodialysis treatment. Contemp Dial Nephrol 1992; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/11\">",
"      Frankenfield DL, McClellan WM, Helgerson SD, et al. Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. Am J Kidney Dis 1999; 33:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/12\">",
"      Daugirdas JT. Linear estimates of variable-volume, single-pool Kt/V: an analysis of error. Am J Kidney Dis 1993; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/13\">",
"      Sherman RA, Cody RP, Rogers ME, Solanchick JC. Accuracy of the urea reduction ratio in predicting dialysis delivery. Kidney Int 1995; 47:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/14\">",
"      Covic A, Goldsmith DJ, Hill K, et al. Urea kinetic modelling--are any of the 'bedside' Kt/V formulae reliable enough? Nephrol Dial Transplant 1998; 13:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/15\">",
"      Cheng YL, Choi KS, Chau KF, et al. Urea reduction ratio that considers effects of ultrafiltration and intradialytic urea generation. Am J Kidney Dis 2001; 37:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/16\">",
"      Traynor JP, Oun HA, McKenzie P, et al. Assessing the utility of the stop dialysate flow method in patients receiving haemodiafiltration. Nephrol Dial Transplant 2005; 20:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/17\">",
"      Kerr PG, Argil&eacute;s A, Canaud B, et al. Accuracy of Kt/V estimations in high-flux haemodiafiltration using per cent reduction of urea: incorporation of urea rebound. Nephrol Dial Transplant 1993; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/18\">",
"      Pflederer BR, Torrey C, Priester-Coary A, et al. Estimating equilibrated Kt/V from an intradialytic sample: effects of access and cardiopulmonary recirculations. Kidney Int 1995; 48:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/19\">",
"      Castro MC, Rom&atilde;o JE Jr, Marcondes M. Measurement of blood urea concentration during haemodialysis is not an accurate method to determine equilibrated post-dialysis urea concentration. Nephrol Dial Transplant 2001; 16:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/20\">",
"      Traynor JP, Geddes CC, Ferguson C, Mactier RA. Predicting 30-minute postdialysis blood urea concentrations using the stop dialysate flow method. Am J Kidney Dis 2002; 39:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/21\">",
"      Owen WF Jr, Meyer KB, Schmidt G, Alfred H. Methodological limitations of the ESRD Core Indicators Project: an ESRD network's experience with implementing an ESRD quality survey. Medical Review Board of the ESRD Network of New England. Am J Kidney Dis 1997; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/22\">",
"      European best practice guidelines for haemodialysis (Part 1). Nephrol Dial Transplant 2002; 17(Suppl 7):25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/23\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/24\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/25\">",
"      Delmez JA, Windus DW. Hemodialysis prescription and delivery in a metropolitan community. The St. Louis Nephrology Study Group. Kidney Int 1992; 41:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/26\">",
"      Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 1994; 121:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/27\">",
"      Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/28\">",
"      Dumler F, Stalla K, Mohini R, et al. Clinical experience with short-time hemodialysis. Am J Kidney Dis 1992; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/29\">",
"      United States Renal Data System. Excerpts from the USRDS 2000 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2000; 36(Suppl 2):S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/30\">",
"      2007 Annual Report: ESRD clinical performance measures project. Am J Kidney Dis Suppl 2008; 51(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/31\">",
"      United States Renal Data System. Excerpts from the USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2007; 49(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/32\">",
"      Hecking E, Bragg-Gresham JL, Rayner HC, et al. Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/33\">",
"      Leonard MB, Stablein DM, Ho M, et al. Racial and center differences in hemodialysis adequacy in children treated at pediatric centers: a North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) report. J Am Soc Nephrol 2004; 15:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/34\">",
"      Chand DH, Brier M, Strife CF. Comparison of vascular access type in pediatric hemodialysis patients with respect to urea clearance, anemia management, and serum albumin concentration. Am J Kidney Dis 2005; 45:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/35\">",
"      Gorman G, Furth S, Hwang W, et al. Clinical outcomes and dialysis adequacy in adolescent hemodialysis patients. Am J Kidney Dis 2006; 47:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/36\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/37\">",
"      Depner T, Daugirdas J, Greene T, et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 2004; 65:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/38\">",
"      Port FK, Wolfe RA, Hulbert-Shearon TE, et al. High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 2004; 43:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/39\">",
"      Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/40\">",
"      Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 2004; 66:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/41\">",
"      Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/42\">",
"      Cheung AK, Greene T, Leypoldt JK, et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/43\">",
"      Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace Ther 2003; 10:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/44\">",
"      Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome--what the HEMO study doesn't tell us: the European viewpoint. Nephrol Dial Transplant 2003; 18:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/45\">",
"      Rocco MV, Cheung AK, Greene T, et al. The HEMO Study: applicability and generalizability. Nephrol Dial Transplant 2005; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/46\">",
"      Greene T, Daugirdas J, Depner T, et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of \"dose-targeting bias\". J Am Soc Nephrol 2005; 16:3371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/47\">",
"      Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/48\">",
"      Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/49\">",
"      Vilar E, Wellsted D, Chandna SM, et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 2009; 24:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/50\">",
"      Shafi T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2010; 56:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/51\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/52\">",
"      Blake PG. Adequacy of dialysis revisited. Kidney Int 2003; 63:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/53\">",
"      Kloppenburg WD, Stegeman CA, Hooyschuur M, et al. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient. Kidney Int 1999; 55:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/54\">",
"      Coyne DW, Delmez J, Spence G, Windus DW. Impaired delivery of hemodialysis prescriptions: an analysis of causes and an approach to evaluation. J Am Soc Nephrol 1997; 8:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/55\">",
"      Ifudu O, Mayers JD, Matthew JJ, et al. Standardized hemodialysis prescriptions promote inadequate treatment in patients with large body mass. Ann Intern Med 1998; 128:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/56\">",
"      Powers KM, Wilkowski MJ, Helmandollar AW, et al. Improved urea reduction ratio and Kt/V in large hemodialysis patients using two dialyzers in parallel. Am J Kidney Dis 2000; 35:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/57\">",
"      Hauk M, Kuhlmann MK, Riegel W, K&ouml;hler H. In vivo effects of dialysate flow rate on Kt/V in maintenance hemodialysis patients. Am J Kidney Dis 2000; 35:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/58\">",
"      Mehta HK, Deabreu D, McDougall JG, Goldstein MB. Correction of discrepancy between prescribed and actual blood flow rates in chronic hemodialysis patients with use of larger gauge needles. Am J Kidney Dis 2002; 39:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/59\">",
"      Lambie SH, Taal MW, Fluck RJ, McIntyre CW. Analysis of factors associated with variability in haemodialysis adequacy. Nephrol Dial Transplant 2004; 19:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/60\">",
"      Ahmed J, Besarab A, Lubkowski T, Frinak S. Effect of differing blood lines on delivered blood flow during hemodialysis. Am J Kidney Dis 2004; 44:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/61\">",
"      Sehgal AR, Leon JB, Siminoff LA, et al. Improving the quality of hemodialysis treatment: a community-based randomized controlled trial to overcome patient-specific barriers. JAMA 2002; 287:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/62\">",
"      Stoffel MP, Barth C, Lauterbach KW, Baldamus CA. Evidence-based medical quality management in dialysis--Part I: Routine implementation of QiN, a German quality management system. Clin Nephrol 2004; 62:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/63\">",
"      Stoffel MP, Barth C, Lauterbach KW, Baldamus CA. Evidence-based medical quality management in dialysis--Part II: Improvement of hemodialysis adequacy. Clin Nephrol 2004; 62:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/64\">",
"      NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. V. Hemodialysis dose troubleshooting. Am J Kidney Dis 2001; 37(Suppl 1):S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/65\">",
"      Schulman, G, Delmez, J, Greene, T, et al. Experience with two dialyzers in series in the HEMO study (abstract). J Am Soc Nephrol 2000; 11:177A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/66\">",
"      Splendiani G, Zazzaro D, Tullio T, et al. Bidialysis: a new technique. Int J Artif Organs 2001; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/67\">",
"      Fritz BA, Doss S, McCann LM, Wrone EM. A comparison of dual dialyzers in parallel and series to improve urea clearance in large hemodialysis patients. Am J Kidney Dis 2003; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/68\">",
"      Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998; 13:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/69\">",
"      Keshaviah P. The solute removal index--a unified basis for comparing disparate therapies. Perit Dial Int 1995; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/70\">",
"      Cheng YL, Shek CC, Wong FK, et al. Determination of the solute removal index for urea by using a partial spent dialysate collection method. Am J Kidney Dis 1998; 31:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/71\">",
"      Depner TA, Greene T, Gotch FA, et al. Imprecision of the hemodialysis dose when measured directly from urea removal. Hemodialysis Study Group. Kidney Int 1999; 55:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/72\">",
"      Marshall MR, Santamaria P, Collins JF. Biostat 1000 and Daugirdas blood-based hemodialysis quantification: agreement and reproducibility. Am J Kidney Dis 1998; 31:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/73\">",
"      Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG. Dose of hemodialysis and survival: differences by race and sex. JAMA 1998; 280:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/74\">",
"      McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998; 9:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/75\">",
"      Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/76\">",
"      Wolfe RA, Ashby VB, Daugirdas JT, et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000; 35:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/77\">",
"      Lowrie EG, Chertow GM, Lew NL, et al. The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int 1999; 56:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/78\">",
"      Lowrie, EG, Lew, NL. The urea reduction ratio (URR): A simple method for evaluating hemodialysis treatment. Contemp Dial Nephrol 1991; (Feb):11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/79\">",
"      Li Z, Lew NL, Lazarus JM, Lowrie EG. Comparing the urea reduction ratio and the urea product as outcome-based measures of hemodialysis dose. Am J Kidney Dis 2000; 35:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/80\">",
"      Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int 2002; 62:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/81\">",
"      Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients. Kidney Int 2004; 66:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/82\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/83\">",
"      Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/84\">",
"      Bommer J. If you wish to improve adequacy of dialysis, urea kinetics, such as Kt/V, may be the wrong parameter to study. ASAIO J 2001; 47:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/85\">",
"      Mercadal, L, Ridel, C, Petitclerc, T. Ionic dialysance: Principle and review of its clinical relevance for quantification of hemodialysis efficiency. Hemodialysis Int 2005; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/86\">",
"      Di Filippo S, Manzoni C, Andrulli S, et al. Ionic dialysance allows an adequate estimate of urea distribution volume in hemodialysis patients. Kidney Int 2004; 66:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/14/6378/abstract/87\">",
"      Gotch FA, Panlilio FM, Buyaki RA, et al. Mechanisms determining the ratio of conductivity clearance to urea clearance. Kidney Int Suppl 2004; :S3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1836 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6378=[""].join("\n");
var outline_f6_14_6378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8619753\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION AND CALCULATION OF KT/V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Computer models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Statistical models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urea reduction ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postdialysis BUN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OPTIMAL KT/V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEMO study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Residual renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Target value",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FREQUENCY OF MEASUREMENT OF DIALYSIS DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CORRECTION OF LOW KT/V VALUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ALTERNATIVES TO KT/V FOR ASSESSING ADEQUACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Solute removal index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-normalized dialysis dose (Kt)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8619753\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1836|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/32/22030\" title=\"figure 1\">",
"      Nomogram to estimate KtV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/7/25725\" title=\"figure 2\">",
"      Changes in BUN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/27/39357\" title=\"figure 3\">",
"      High and standard dose HEMO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/58/36781\" title=\"figure 4\">",
"      High and low flux HEMO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/58/35745?source=related_link\" title=\"calculator 1\">",
"      Calculator: Kt/V Dialysis Dose Daugirdas Formula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=related_link\">",
"      Arteriovenous fistula recirculation in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=related_link\">",
"      Prescribed versus delivered dialysis: Importance of dialysis time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_14_6379="Specialized cath techniques";
var content_f6_14_6379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specialized cardiac catheterization techniques",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Transseptal puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct left ventricular puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dual hi-fidelity micromanometer catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple arterial access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long sheaths/double lumen catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endomyocardial biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial pressure/drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcoronary pressure/flow velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraarterial/intracardiac ultrasound imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indication dilution curves",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6379=[""].join("\n");
var outline_f6_14_6379=null;
var title_f6_14_6380="Dust mite avoidance PI";
var content_f6_14_6380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for avoiding dust mites in your home",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First: Bedrooms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cover your pillows and mattresses with special zippered covers that keep dust mites away from you",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every week, wash your sheets, pillowcases, and blankets in hot water with detergent, or dry them in an electric dryer on the hot setting. If possible, don't use a comforter. Instead, use a blanket that can be washed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use washable, vinyl, or roll-type window covers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove clutter, stuffed animals and other soft toys, and fabric-covered furniture. If you can't take the stuffed animals out of the bedroom, wash them every week.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If possible, remove carpets. Instead, use area rugs that can be cleaned or washed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Second: Rest of house",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to reduce the amount of fabric-covered furniture you have, especially old sofas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If possible, replace carpets with (non-carpet) flooring. This includes carpets on concrete slabs or over poorly ventilated crawl spaces.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every week, vacuum the house with a vacuum that has a \"HEPA filter\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use washable, vinyl, or roll-type window covers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure that the humidity in the home is less than 50 percent. Do not use a humidifier.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Third: Changing houses*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People with allergies and asthma do not usually need to move, except if they live in a basement or in a home that is very damp and wet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you are allergic to dust mites or mold, you might have fewer symptoms if you move to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; An apartment on or above the 2nd floor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; A home with wooden floors and bedrooms on the 2nd floor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The average family in the United States moves about every four years.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6380=[""].join("\n");
var outline_f6_14_6380=null;
var title_f6_14_6381="PUVA indications";
var content_f6_14_6381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PUVA indications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        FDA approved indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Off label dermatologic uses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mycosis fungoides/Sezary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histiocytosis X (Langerhans cell histiocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Papulosquamous/dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atopic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seborrheic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic hand dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Palmoplantar pustulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parapsoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pityriasis lichenoides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphomatoid papulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Photosensitivity dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polymorphous light eruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Erythropoietic protoporphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Solar urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic actinic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other pruritic dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dermographism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aquagenic urticaria/pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polycythemia vera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urticaria pigmentosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prurigo nodularis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other immunologic dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alopecia areata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Graft-versus-host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Morphea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Linear scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Miscellaneous dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transient acantholytic dermatosis (Grover's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pigmented purpuric dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ichthyosis linearis circumflexa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Scleromyxedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Generalized granuloma annulare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Methoxsalen capsules approved for this indication.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Methoxsalen solution and trioxsalen are approved for this indication.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Morison WL. PUVA Photochemotherapy. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Saunders Elsevier, Philadelphia 2007. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6381=[""].join("\n");
var outline_f6_14_6381=null;
var title_f6_14_6382="Insulin response to arginine";
var content_f6_14_6382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute serum insulin response to arginine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The acute serum insulin response to arginine increases in an approximately linear manner as blood glucose concentrations increase from 100 to 300 mg/dL (5.6 to 16.7 mmol/L), reaching a plateau above 450 mg/dL (25 mmol/L). To convert insulin values to pmol/L, multiply by 6; to convert blood glucose values to mmol/L, multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74:1318.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6382=[""].join("\n");
var outline_f6_14_6382=null;
var title_f6_14_6383="Biliary atresia type 1";
var content_f6_14_6383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biliary atresia type 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biliary atresia type 1. No visualization of biliary tree. Opacification of normal pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright &copy; 1997 Taylor and Francis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_14_6383=[""].join("\n");
var outline_f6_14_6383=null;
